# Virginia Breast & Cervical Cancer Early Detection Program Orientation Manual (Version 06/03)

Division of Women's and Infants' Health
Office of Family Health Services
Virginia Department of Health

# TABLE OF CONTENTS

CONTACT INFORMATION	
Contact Information.	2
Administrative Provider Site Information	3
Screening Provider Information	4
CASE MANAGEMENT	5
BCCEDP Case Management Job Description	6
BCCEDP Annual Provider Site Report	9
Matching Funds Form	20
Reported Screenings by Month	
Turn-Around Times/Patient Notification of Results	22
ELIGIBILITY	23
Eligibility for Enrollment	24
2003 Federal Poverty Guidelines	
BREAST CANCER SCREENING & FOLLOW-UP	26
Model Clinical Categories for CBE	27
ACR Reporting Categories	28
Breast Cancer – TNM Cancer Staging	
Timeliness & Adequacy of Breast Cancer Screening and Follow-up	30
CERVICAL CANCER SCREENING & FOLLOW-UP	31
BCCEDP Cervical Screening Policy	32
ASCCP Guidelines	35
HPV Testing	36
DATA	37
RECOMMENDED FORMS	43
QUALITY ASSURANCE	51
BCCEDP Audit Guidelines	
Audit Report	55
Documentation of Patient Education	59
Performance Indicators	60
MEDICAID	62
BCCEDP Policy Related to Medicaid Treatment Reimbursement	63
Sample Letter to Physician Re: Medicaid	65
FREQUENTLY ASKED QUESTIONS	66
BILLING	
Billing Policy	
Getting Paid	
Sample Invoice	
BCCEDP Approved Medicare Procedure Codes	
SAMPLE LETTERS	80
APPENDICES	
Appendix A: Algorithms from the Consensus Guidelines for the Management of	
Cervical Cytological Abnormalities	
Appendix B: BCCPTA Medicaid Application/Redetermination Form	
Appendix C: Medicaid BCCPTA Policy (M0320.312)	
Appendix D: Public Education & Outreach Work Plan	

# **Contact Information**

## **CONTACT INFORMATION**

Mailing Address: (use for FEDEX mailing address as well) (NEW!)
Virginia Breast & Cervical Cancer Early Detection Program (BCCEDP)
Virginia Department of Health
109 Governor Street, Eighth Floor (P.O. Box 2448)
Richmond, VA 23219

• Contact numbers: (NEW!)

Phone: (804) 864-7761 FAX: (804) 864-7763

## • BCCEDP Office Directory:

Name	Title	Office Phone	Office Fax	E-Mail Address
TT 1 TT 1	D D	(004) 054 7755	(004) 054 7750	77 1 77 1 0 11 1 1 1
Kathy Heise	Program Director	(804) 864-7756	(804) 864-7763	Kathy.Heise@vdh.virginia.gov
E D 1'		(004) 064 5550	(004) 064 7760	
Fran Darlington	Quality Improvement	(804) 864-7758	(804) 864-7763	Fran.Darlington@vdh.virginia.gov
	Nurse Manager			
Gail Jennings	Data, Surveillance and	(804) 864-7757	(804) 864-7763	Gail.Jennings@vdh.virginia.gov
	Evaluation Manager			
Nancy Malone	Quality Improvement	(804) 864-7760	(804) 864-7763	Nancy.Malone@vdh.virginia.gov
	Nurse			
Beth Ehrensberger	Public Education	(804) 864-7759	(804) 864-7763	Beth.Ehrensberger@vdh.virginia.gov
	Manager			
Amare Jampani	Data Quality Control	(804) 864-7762	(804) 864-7763	Amare.Jampani@vdh.virginia.gov
VACANT	Program Support	(804) 864-7761	(804) 864-7763	

Our Web page address is <a href="www.vahealth.org/breastcancer">www.vahealth.org/breastcancer</a>

Revised 8/26/03 2

# ADMINISTRATIVE PROVIDER SITE INFORMATION

Complete an	nd return to BCCE	DP- FAX: (804) 864-	7763 or E-mail: Gail.Jenn	ings@vdh.virginia.gov	
Administrat	ive Provider Site _				
Address:					
	Agency/Organ	ization			
	Street Address			Bldg./Room/Suite	
	City/Town		State	Zip Code	
Agency We	b Site Address: _				
Key Contac	ets:	Name	Telephone	FAX	Email
Director/Ad	ministrator				
Case Manag	ger/Coordinator				
Fiscal Mana Coordinator	ger/Billing				
Community Worker	Lay Outreach				
Other:					
Other:					
		•	u want it listed on the BC e Map of Providers by Co		
Contact:			Telephone Nur	mber(s):	
Counties/Ci	ties Served:				

# **SCREENING PROVIDER INFORMATION**

Administrative Provider Site				
Please list your screening providers for breast and cervical cancer. <b>Plea</b>				nostic services and/or treatment services
Screening Provider:				
FIN/TIN (9-digit #):				
Mailing Address:				
Telephone:				
Organization Type: (check one)				
☐ Local Health Department	☐ Private	e Hospital	☐ Medical/Professional	School (university based)
☐ Community Health Center/Free	Clinic $\Box$	Other:		
Service Type: (check all that apply	7)			
☐ Breast screening (i.e., mammogr	ram)	Cervical screen	ning (i.e., pelvic exam, Pap Sn	near)
☐ Breast diagnostic service		Cervical diagn	ostic service	
☐ Breast treatment service		l Cervical treatn	nent service	

# **Case Management**

#### BCCEDP CASE MANAGEMENT JOB DESCRIPTION

According to the CDC, case management is a systematic process of identification and outreach, assessment, planning, service coordination, monitoring, evaluation and advocacy through an approach which is responsive to the specific multiple and changing needs of individual clients and families. It ensures that women enrolled in the BCCEDP receive timely and appropriate rescreening, diagnostic and treatment services.

#### Assessment (10%)

- Demonstrates the ability to interview clients to ensure completeness and accuracy of data and to determine or redetermine eligibility for the BCCEDP.
- Obtains written consent from the client prior to delivery of services at the initial screening and again prior to re-screening, on an annual basis. Ensures that consent forms for screening and treatment services are explained and the client is given the opportunity to ask questions before signing.

#### Planning (35%)

- Arranges client transportation to clinical services as needed.
- Arranges for the services of an interpreter when needed.
- Maintains contacts with community agencies to coordinate the delivery of services.
- Refers patients to appropriate community resources for services not covered by the BCCEDP. Ensures that all women diagnosed with breast and/or cervical cancer receive financial screening for other indigent programs in the community as needed. Services should demonstrate the case manager's resourcefulness in obtaining volunteer or in-kind services for the client or in obtaining necessary entitlements. Also ensures that the appropriate referrals for treatment are carried out. Refers eligible women diagnosed with breast or cervical cancer under the *Breast and Cervical Cancer Prevention and Treatment Act* to Medicaid.
- Maintains a tracking system for all women enrolled in the BCCEDP to ensure appropriate follow-up and rescreening services.
- Ensures that all women enrolled in the BCCEDP receive timely and appropriate screening, re-screening, diagnostic work-up and treatment services outlined in the BCCEDP Medical Protocol Manual.
- Establishes outreach efforts to identify BCCEDP eligible clients or identifies responsible staff to carry out these efforts. If recruitment and/or enrollment activities

Rev 12/2001 6

are carried out by other staff, there should be coordination with that staff member to ensure that all women who inquire about the BCCED Program are contacted, interviewed for eligibility, and scheduled for services, if they qualify for the Program.

- Ensures that clients receive services in accordance with the Civil Rights Act, the American with Disabilities Act and other relevant federal, state and local laws.
- Ensures that a system is in place for accommodating walk-in clients.
- Responsible for ensuring that a clinical breast exam is performed by a qualified health professional on all clients receiving breast and/or cervical cancer screening services.
- Ensures that agreements with subcontractors are in writing, contain authorized signatures, stipulated prices, and include BCCEDP applicable quality assurance and contractual requirements.

#### **Implementation** (45%)

- Demonstrates skill in the use of computer software such as word processing and database applications. Ability to collect and organize data sufficient to maintain accurate and complete records, and to prepare reports in accordance with state and federal guidelines. Submits BCCEDP data forms to the VDH data manager within sixty (60) days of the initial screening.
- Initiates and maintains a medical record containing documentation of consent, emergency contact, screening performed, test referrals and their results, and follow-up of medical problems throughout diagnosis and treatment. Ensures that documentation is organized so that the status of the client's medical care and any follow-up efforts by staff can be determined at any point in time.
- Obtains mammogram and Pap smear reports within time frames designated by the VABCCEDP.
- Notifies patients of normal Pap smear screening results within time frames designated by the VABCCEDP.
- Notifies patients of abnormal Pap smear and abnormal mammogram results within five working days of the receipt of those results by the provider site.
- Obtains approval from the Virginia State BCCEDP office for breast ultrasound studies.
- Obtains diagnostic work-up, diagnosis and/or treatment information on all women whose initial screening was paid for the BCCEDP whether their subsequent diagnostic work-up and/or treatment was through a BCCEDP provider or through an

Rev 12/2001 7

outside provider. Obtains Pap smear, CBE, and mammography screening results performed recently elsewhere from outside providers who have referred women to the BCCEDP for services.

- Ensures that no more than sixty-(60) days elapse between patient screeening and final diagnosis.
- Ensures that no more than sixty-(60) days elapse between final diagnosis and initiation of treatment.
- Maintains privacy and confidentiality in all services provided to BCCEDP clients.
- Ensures that patients receive breast and cervical cancer education that is documented, culturally sensitive, and presented at a literacy level appropriate for the client.
- Ensures that clients receiving screening, re-screening, and case management services through the BCCEDP shall receive continuity of care. Responsible for the transfer of records to appropriate providers after obtaining written consent from the client.
- Provides and participates in professional education activities.
- Completes necessary reporting requirements for all program areas.
- Responsible for following up with clients who have missed appointments and documenting the contacts in the medical record.
- Maintains current documentation of compliance with the MQSA and CLIA certification.
- Ensures that the Virginia BCCEDP is billed on a monthly basis at the agreed upon unit cost for reimbursable services performed. The billing process is monitored to assure that the correct units are billed, the appropriate codes are used, and there is no duplicate billing (either on the part of the subcontractors or by the provider agency).

#### Evaluation (10%)

- Participates in program review to meet quality assurance requirements, including scheduled site visits by VDH staff.
- Performs or ensures the performance of self-quality assurance audits.
- Conducts periodic self-review of medical records to assure that all medical and eligibility services are documented.

Rev 12/2001

# **BCCEDP ANNUAL PROVIDER SITE REPORT**

Due: TBA

Submit to the VABCCEDP Data Manager

## **Provider Information**

## **Reporting Period for Provider Site Report:**

New Provider Sites: TBA

■ FY 2003 Provider Sites: TBA

Date Completed:									
Provider Sit	Provider Site:								
Report Com	pleted/Sub	mitted By:							
Name:									
Title:									
Address:									
City:			State		Zip				
Phone:									
Fax:									

Submission Date: <u>TBA</u>

Submit by 5 pm on the above date by E-mail (Gail.Jennings@vdh.virginia.gov), Fax (804-864-7757), or

U.S. Mail:

Virginia BCCEDP, Virginia Department of Health ATTN: Gail Jennings, Data., Surveillance and Evaluation Manager 109 Governor Street, Eighth Floor (P.O. Box 2448) Richmond, Virginia 23219

# **Public Education & Outreach (incl. Coalitions & Partnerships)**

1. Please indicate how many people and the total FTE (i.e., full-time equivalency position) dedicated to public education and outreach in each of the listed local settings. Also, indicate if any of these positions are supported by state BCCEDP funds. Please use the space below for comments.

Local Setting	Number of People	<b>Total Aggregate FTE</b>
YWCA		
Local health department		
Tribal clinic		
ACS		
Community groups		
Housing project		
Cooperative extension		
Provider Site		
Community Health Center		
Hospital		
University		
Mobile Screening Site		
Business (e.g., beauty salon, factory)		
Total		

#### **Definitions:**

**Total FTE dedicated** – the number of full-time equivalents (FTEs) that are providing public education and outreach activities at the local settings (**Example:** if 10 local public health departments employ 3 outreach workers per site, and each outreach worker spends 15% of their time on recruiting women to be screened at the BCCEDP sites, the table would indicate 30 for the total number of people per sites (10 x 3) and 4.5 FTEs (30 x 0.15).

GENERAL COMMENTS:					

2. Select and rank up to **five** (5) primary strategies you used to promote screening <u>and re-screening</u> at the local level (see list of strategies and codes below). Leave blank if not appropriate.

Priority Population	Strategy (ran	k ordered)			
All eligible women	1.	2.	3.	4.	5.
African American women	1.	2.	3.	4.	5.
Alaska Native women	1.	2.	3.	4.	5.
Asian/Pacific Islander women	1.	2.	3.	4.	5.
Women w/ disabilities	1.	2.	3.	4.	5.
Women who speak English as a	1.	2.	3.	4.	5.
second language					
Hispanic women	1.	2.	3.	4.	5.
Lesbians	1.	2.	3.	4.	5.
Native American/American	1.	2.	3.	4.	5.
Indian women					
Older women (age 50+)	1.	2.	3.	4.	5.
Rural women	1.	2.	3.	4.	5.

#### **Definitions:**

**Primary strategies for initial screening** – the strategies that represent over 75% of the total efforts to recruit women for screening or re-screening (**Example:** a local program that relies on direct mail, home visits and hotlines to recruit women to enroll in the program).

GENERAL COMMENTS:						

#### **Strategies (use code numbers):**

Radio messages	12 -	Newsletters to public
Newspaper messages	13 -	Hotlines for referral
Television messages – PSAs	14 -	Direct mail
TV paid advertising	15 -	Culturally specific brochures
Billboards	16 -	Resource guides
Bus or commuter placards	17 -	Work site presentations (awareness)
Taxi placards	18 -	Church-based presentations (awareness)
Posters	19 -	Community-based presentation (awareness)
Special promotional events	20 -	Direct recruitment
Celebrity support	21 -	Provider referral
Flyers – population based	22 -	Customer referral
	Newspaper messages Television messages – PSAs TV paid advertising Billboards Bus or commuter placards Taxi placards Posters Special promotional events Celebrity support	Newspaper messages Television messages – PSAs TV paid advertising Billboards Bus or commuter placards Taxi placards Posters Special promotional events Celebrity support  13 - 14 - 15 - 16 - 18 - 19 - 20 - 21 -

	Do you facilitate a regular meeting of a local coalitic cervical cancer screening? NO		assist in public outreach and education on breast and
* If	YES, how often does the coalition meet? (check one	e)	
	Once a year twice a year 3-4 times	s a year	5-11 times a year 12+ times a year
4.	How many members are on the local public education	on coalition?	
5.	List whether or members of the following groups are	e members of y	our local public education coalition:
	African American		Health professionals (incl. program providers)
	Native American/American Indian		Legislators (state/local elected official)
	Asian and Pacific Islander American		Local government
	Hispanic/Latina		Local health department
	Foreign born women		Professional organization
	Lesbian		Other government agency (e.g., Office of Mental
	People with disabilities		Health)
	Rural women		Health Department staff (e.g., cancer registry,
	Consumers (e.g., current or former BCCEDP		lab/QA expert)
	clients)		Voluntary organization
	Survivors		Cancer center
	Women over 50		University
	American Cancer Society		Outreach program
	Cancer Information Services (CIS)		Hospital
	Medicaid representative		Social worker
	Media		Counselor
	Advocacy group		Researcher
	Churches/religious organization		

# **Professional Education**

1. Indicate the training that staff have received during this reporting period, the type of staff that received training, the number of program and non-program staff members who participated, the source of the training, and whether or not evaluation was done by the training group. You may list more than one type of staff for each training topic. Refer to codes for Staff on page 7.

Training Topic	Number of	<b>STAFF</b>	# Program	# Non-	Source	<b>Evaluation</b>
	trainings	(list up to three)	Providers	Program Providers	(BCCEDP or Other)	(Yes or No)
Administrative procedures		1.				
		2.				
		3.				
Epidemiology, trends		1.				
		2.				
		3.				
National, State and Program		1.				
guidelines		2.				
D 311		3.				
Resources available		1.				
		2. 3.				
Office support systems		1.				
Office support systems		2.				
		3.				
General breast cancer update		1.				
General breast cancer apaute		2.				
		3.				
Clinical breast examination		1.				
techniques		2.				
1		3.				
Self-breast examination		1.				
instruction		2.				
		3.				
Providing mammograms		1.				
		2.				
		3.				
Interpreting mammograms		1.				
		2.				
		3.				
Radiology tech in-services		1.				
for breast cancer		2.				
		3.				
General cervical cancer		1.				
update		2.				
прише		3.				
Obtaining Pap smears		1.		<u> </u>		
2 - Samuel ap omedia		2.				
		3.				
Interpreting Pap smears		1.				
1		2.				
		3.				

Training Topic	Number of trainings	STAFF (list up to three)	# Program Providers	# Non- Program Providers	Source (BCCEDP or Other)	Evaluation (Yes or No)
Performing bimanual pelvic examinations		1. 2. 3.				
Colposcopy		1. 2. 3.				
Cytotechnology inservices for cervical cancer		1. 2. 3.				
Treatment options		1. 2. 3.				
Referral options		1. 2. 3.				
Counseling patients regarding behavioral risks		1. 2. 3.				
Counseling patients regarding abnormal results		1. 2. 3.				
Targeting priority populations		1. 2. 3.				
Enhancing communi-cation with older and targeted women		1. 2. 3.				
Sensitivity training involving different cultures and practices		1. 2. 3.				
Support groups and resources in community		1. 2. 3.				

#### **Definitions:**

**Training** – an independent learning event (lecture, demonstration, interactive video, journal, newsletter, conferences, workshops, seminars, symposia, etc.) that helps health care personnel to maintain or learn skills, knowledge and attitudes relevant to the provision of health care.

**Program and non-program participants** – program participants are those that have a contractual or informal agreement with the program. Non-program participants are health care providers that are practicing and have no contractual or data relationship to the program but wished to attend the training.

#### **Staff:**

1 - Physicians **9 -** Radiology Technologists 18 - Clinical/Technical Support Staff 2 - Physician Assistants 10 - Medical Physicists **19 -** Program Administrators 3 - Nurses (registered, licensed, public 11 - Health Educators 20 - Medical/Tumor Registry Personnel health or vocational) 12 - Outreach Workers 21 - Students **4 -** Nurse Practitioners 13 - Social or Case Workers 22 - Data Managers 5 - Medical Assistants 14 - Case Managers 23 - Research Statistician **6** - Cytotechnologists 15 - Office Managers 7 - Pathologists 16 - General Office Support Staff 8 - Radiologists 17 - Clerical Support Staff 2. How many staff members have been sent to a BCCEDP orientation training in the current reporting period?

GENERAL COMMENTS:	

#### **Clinical Services**

#### A. Service Delivery

1. Indicate the number of sites providing clinical screening and diagnostic services for program-eligible women paid for by program funds (including match) for this reporting period. Include subcontracting sites or facilities; do not include individual practitioners (e.g., Dr. Smith) who belong to a facility or practice.

	Number of Sites
Total Unduplicated Sites (any service)	
Mammography (with or without CBE) screening	
Cervical screening only	
Cervical screening with CBE	
Breast Diagnostic Services	
Cervical Diagnostic Services	

2. Enter the customary charge for each of the approved procedures below.

Screening/Diagnostic Procedures	Medicare CPT Code	<b>Customary Charge</b>
Mammogram (screening)	76092	\$
Pap smear	88141	\$
Office visit – new patient, 30 minutes	99203	\$
Colposcopy with biopsy	57455	\$
Colposcopy without biopsy	57452	\$
Diagnostic mammogram (bilateral)	76091	\$
Breast Ultrasound	76645	\$
Cytopathology (evaluation of fine needle aspirate)	88172	\$
Biopsy – incisional	19101	\$
Biopsy - excisional	19120	\$
Consultation visit – 30 minutes	99242	\$
Pathology - breast	88307	\$
Pathology - cervical	88305	\$

#### **Definitions:**

**Program funds** – the funds received from the CDC through the Virginia BCCEDP and matching resources obtained by the applicant (**Example:** total funds indicated on the Notice of Grant Award).

Cervical screening – pelvic exam, Pap smear.

**Breast diagnostic** – diagnostic mammogram or additional mammographic views, ultrasound, fine needle aspiration, stereotactic or needle core biopsy, etc.

Cervical diagnostic – colposcopy, cervical biopsy, LEEP, etc.

Medicare CPT Code – BCCEDP approved Medicare Procedure Codes based on the year 2003 Medicare Rate Schedule.

Customary charge – the usual and customary Provider Site charge.

3.	<ol><li>How many counties and/or independent cities does your Provi</li></ol>	der Site cover? List counties/cities below
4.	4. How many women diagnosed with cancer have been referred	to Medicaid under the BCCPTA?
	Breast Cervical	

#### **B.** Quality Assurance

1. During this reporting period, how many mammography facilities (portable, stationary, and mobile mammography facilities) in your geographic area that are providing BCCEDP-funded services and are certified under the Mammography Quality Standards Act of 1992 (MQSA) administered by the Food and Drug Administration (FDA)? Indicate how many radiological facilities screening with program funds are reporting results of mammographic examinations using the American College of Radiology Breast Imaging Reporting System (BIRADS).

Group	MQSA Ce	rtification	<b>ACR Breast Imaging</b>	Total #
	Certified Provisional		Reporting - #	
Mobile mammography				
Portable mammography				
Stationary mammography				

2. During this reporting period, how many laboratories providing cytology services for the program are in compliance with CLIA '88, and how many use the Bethesda system for reporting screening results?

	Number Providing Services	CLIA '88 Compliance	Bethesda System Reporting
In-state			
Out-of-state			
Total			

#### **MATCHING FUNDS FORM**

Non-Federal matching funds in the amount of \$1 for every \$3 of Federal funds awarded is required. Please provide in the table below your matching funds (projected and actual) for FY 2003-2004 (June 30, 2003 – June 29, 2004) by the deadline date. Your matching funds should equal 33% of your total grant allocation. For example, if you receive \$100,000 to provide BCCEDP services, your in-kind match would be \$33,000.

#### **Non-Federal Cash Resources and Amounts:**

Source	Projected Amount By July 31, 2003	Actual Amount By June 29, 2004
• Cash donations	\$	\$
Community fund-raising	\$	\$
• Other grants or awards (e.g., Komen, Avon)	\$	\$

## **Non-Federal Non-Cash Resources and Amounts:**

Source	Projected Amount By July 31, 2003	Actual Amount By June 29, 2004
• Donated vehicles and equipment (e.g., vans for transportation, laboratory equipment, computers)	\$	\$
• Donated clinical services (e.g., professional salaries)	\$	\$
Donated non-clinical services (e.g., clerical salaries)	\$	\$
• Donated supplies (e.g., educational materials, promotional materials)	\$	\$
• Donated media time (e.g., television, radio, print)	\$	\$
Donated professional time (e.g., service on coalitions, advisory committees, advertising/marketing consultation)	\$	\$

Revised June, 2003 20

#### REPORTED SCREENINGS BY MONTH

Provider Site:	

- (1) Fill in the following rows for each month.
- (2) Report separately the number of new screenings and rescreens.
- (3) The total and cumulative total will be calculated for you.
- (4) Provide a date when you submit this form to VDH
- (5) Submit by the Day 5 of the following month.
- (6) FAX (804-864-7763) or email (Gail.Jennings@vdh.virginia.gov) your report to the Data Manager.

	Jul-03	Aug-03	Sep-03	Oct-03	Nov-03	Dec-03	Jan-04	Feb-04	Mar-04	Apr-04	May-04	Jun-04	Total
# New Screens													0
# Rescreens													0
Total	0	0	0	0	0	0	0	0	0	0	0	0	0
Cumulative													
Total	0	0	0	0	0	0	0	0	0	0	0	0	
Data Submitted	08/01/03												

Note: Formulas are entered in the Total and Cumulative Total cells to add New Screens and Rescreens in each column. Complete only the New Screens and Rescreens cells.

#### TURN-AROUND TIMES/PATIENT NOTIFICATION OF RESULTS

Case managers shall receive Pap smear and mammogram results within **16 business days** of the date of service.

Case managers shall notify the patient of her <u>abnormal</u> Pap smear and <u>abnormal</u> mammogram results within <u>five business days</u> of the receipt of those results by the provider site

Case managers shall notify the patient of her **normal** Pap smear result within **10 business days** of the receipt of those results by the provider site.

Informing patients of normal mammogram results will be performed by the mammography center.

# **Eligibility**

#### **ELIGIBILITY FOR ENROLLMENT**

- **☑** Female
- ☑ Of the women enrolled, 80% must be age 50-64; 20% may be age 40-49
- ☑ Income is 200% of Poverty Level or Less
- ☑ Resident of the United States
- ☑ Primary Residence in Virginia
- ☑ Underinsured or Uninsured

(Note: women who have never or rarely been screened for cervical cancer and minority women are considered a priority target population)

Rev 04/2003 24

## 2003 FEDERAL POVERTY GUIDELINES

(effective 06/30/2003 thru 06/29/2004)

<b>Number in Family</b>	200% FPL								
	Gross Yearly Salary	Gross Monthly Income*	Approximate Hourly Income**						
1	\$17,960	\$1,497	\$8.64						
2	\$24,240	\$2,020	\$11.66						
3	\$30,520	\$2,544	\$14.68						
4	\$36,800	\$3,067	\$17.70						
5	\$43,080	\$3,590	\$20.72						
6	\$49,360	\$4,144	\$23.74						
7	\$55,640	\$4,637	\$26.75						
8	\$61,920	\$5,160	\$29.77						
If more than eight, add \$6,280 (yearly)									
for each child	\$6,280	+\$523	+\$3.02						

SOURCE: Federal Register, Vol. 68, No. 26, February 7, 2003, pp. 6456-6458.

<sup>\*</sup>Divided by 12 months and rounded to the nearest dollar.

<sup>\*\*</sup>Assumes a full-time job for a full year (2080 hours).

# **Breast Cancer Screening & Follow-up**

## MODEL CLINICAL CATEGORIES FOR CBE

- 1. Normal Exam
- 2. Benign Finding (such as fibrocystic changes, diffuse lumpiness or nodularity)
- 3. Discrete palpable mass (includes masses that may be cystic or solid)
- 4. Bloody or serous nipple discharge
- 5. Nipple or areola scaliness
- 6. Skin dimpling or retraction
- 7. Previous normal CBE in past 12 months-CBE not done today
- 8. CBE not done today-other or unknown reason
- 9. CBE refused

<b>Clinical Categories</b>	MDE Categories
1,2	1=normal/benign findings—schedule for a routine CBE in one year
3,4,5,6	2=abnormality suspicious for cancer—diagnostic evaluation needed
7	3=not needed
8,9	4=needed but not performed at this visit (includes refused)

# ACR REPORTING CATEGORIES DEFINITIONS, AND MAMMOGRAPHY FOLLOW-UP

Recommended follow-up by the BCCEDP Medical Advisory Task Group is indicated in italics

		N DEFINITION/RECOMMEDED FOLLOW-UP		
CATEGORY	DESCRIPTION			
1	Negative	There is no reason for comment. The breasts are symmetrical and no masses, architectural disturbances or suspicious calcifications are		
		present. Recommend routine annual mammogram for women over 40		
2	Benign	This is also a negative mammogram, but the interpreter may wish to		
	Finding-	describe a benign finding. Involuting calcified fibroadenomas,		
	Negative	multiple secretory calcifications, fat containing lesions such as oil		
		cysts, lipomas, galactoceles, and mixed density hamartomas all have		
		characteristic appearances, and may be labeled with confidence. The		
		interpreter might wish to describe intramammary lymph nodes,		
		implants, etc. while still concluding that there is no mammographic		
		evidence of malignancy. Recommend routine annual mammogram		
		for women over 40.		
3	Probably	A finding placed in this category should have a very high probability		
	Benign	of being benign. It is not expected to change over the follow-up		
		interval, but the radiologist would prefer to establish its stability.		
		Short-term follow-up-repeat mammogram in three to six months		
		and/or surgical evaluation if recommended by the physician.		
4	Suspicious	These are lesions that do not have the characteristic morphologies of		
	Abnormality	breast cancer but have a definite probability of being malignant. The		
		radiologist has sufficient concern to urge a biopsy. If possible, the		
		relevant probabilities should be cited so that the patient and her		
		physician can make the decision on the ultimate course of action.		
~	TT' 11	Diagnostic mammogram and/or additional work-up within one month		
5	Highly	These lesions have a high probability of being cancer. Appropriate		
	Suggestive of	action should be taken. Diagnostic mammogram and/or additional		
0	Malignancy	work-up within <u>one</u> month.		
0	Assessment	This almost always used in a screening situation and should rarely be		
	Incomplete	used after a full imaging work-up. A recommendation for additional		
		evaluation should be made including the use of spot compression,		
		magnification, special mammographic views, ultrasound, aspiration, etc. <i>Diagnostic mammogram and/or additional work-up within one</i>		
		month.		
	Unsatisfactory	Repeat screening mammogram immediately.		
	Not Indicated	Screening mammogram within one to two years of last screening		
	1 TOT IIIUICAIEU	based on ACS guidelines.		
	Indicated, Not	Patient refused or failed to keep appointment-try to reschedule as		
	Performed	soon as possible.		
	1 CITOTIFICU	soon as possible.		

Categories, descriptions and definitions from BI-RADS, Second Edition, September 1995 AN OVERALL (SUMMARY) IMPRESSION:

All final impressions should be complete with each lesion fully categorized and qualified. An indeterminate reading should only be given in the mammography screening setting where additional evaluation is recommended before a final opinion can be rendered. In the screening situation a suggestion for the next course of action should be given if the study is not conclusive (magnification, ultrasound, etc.)

Interpretation is facilitated by recognizing that most mammograms can be categorized under few headings. If a suspicious abnormality is detected, the report should indicate that biopsy should be considered. This is an assessment where the radiologist has sufficient concern that a biopsy is warranted unless there are other reasons why the patient and her physician might wish to defer the biopsy. Whenever possible, the present mammogram should be compared to previous studies. The radiologist should use judgment in how vigorously to pursue previous studies.

# **BREAST CANCER - TNM CANCER STAGING**

STAGE 0	Ti.s.	NO	MO
STAGE I	T1	NO	MO
STAGE IIA	TO, T1	N1	MO
	T2	NO	MO
STAGE IIB	T2	N1	MO
	Т3	NO	MO
STAGE IIIA	T0,T1,T2	N2	MO
	Т3	N1,N2	M0
STAGE IIIB	Any T	N3	MO
	T4	Any N	MO
STAGE IV	Any T	Any N	M1

# BREAST CANCER - PRIMARY TUMOR (T)

TX	Primary tumor cannot be assessed
TO	No evidence of primary tumor
Ti.s.	Carcinoma in situ: intraductal carcinoma, lobular carcinoma in situ, or Padget's disease with
	no tumor.
T1	Tumor 2 cm or less in greatest dimension
T1A	Tumor 0.5 cm or less in greatest dimension
T1B	Tumor more than 0.5 cm but not more than 1 cm in greatest dimension
T1C	Tumor more than 1 cm but not more than 2 cm in greatest dimension
T2	Tumor more than 2 cm but not more than 5 cm in greatest dimension
T3	Tumor more than 5cm in greatest dimension
T4	Tumor of an size with direct extension to chest wall or to skin
T4a	Extension to chest wall
T4b	Edema (including peau d'orange) or ulceration of the skin of the breast or satellite skin
	nodules confined to the same breast
T4c	Both T4a and T4b
T4d	Inflammatory carcinoma

#### **BREAST CANCER - REGIONAL LYMPH NODES (N)**

NX	Regional lymph nodes cannot be assessed (e.g., previously removed)			
N0	No regional lymph node metastases			
N1	Metastasis to movable ipsilateral axillary lymph node(s)			
N2	Metastases to ipsilateral axillary nodes fixed to one another or to other structures			
N3	Metastases to ipsilateral internal mammary lymph node(s)			

#### BREAST CANCER - DISTANT METASTASIS (M)

MX	Presence of distant metastasis cannot be assessed
MO	No evidence of distant metastasis
M1	Distant metastases (including metastases to ipsilateral supraclavicular lymph nodes

# TIMELINESS & ADEQUACY OF BREAST CANCER SCREENING AND FOLLOW-UP

No	CBE	Mammogram * #	Diagnostic Procedures		
1	Normal	a) Negative	No work-up required ++		
		b) Benign			
		c) Probably Benign			
2	Abnormal	a) Negative	One or more of the following procedures must be performed:		
		b) Benign	a) Repeat breast exam by a surgeon.		
		c) Probably Benign	b) Ultrasound		
		d) Assessment Incomplete	c) Biopsy/Lumpectomy		
			d) d) Fine Needle/Cyst Aspiration		
3	Abnormal	a) Suspicious Abnormality	One or more of the following procedures must be performed:		
		b) Highly Suggestive of	a) Biopsy/lumpectomy		
		Malignancy	b) Fine Needle/Cyst Aspiration		
4	Normal	Suspicious Abnormality	One or more of the following procedures must be performed:		
			a) Repeat breast exam by a surgeon		
			b) Ultrasound		
			c) Biopsy/Lumpectomy		
			d) Fine Needle/Cyst Aspiration		
5	Normal or	Highly Suggestive Of Malignancy	One or more of the following procedures must be performed:		
	Abnormal		a) Biopsy/Lumpectomy		
			b) Fine Needle/Cyst Aspiration		
	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \				
6	Normal	Assessment Incomplete	One or more of the following procedures must be performed:		
			a) Additional mammographic views		
			b) Ultrasound		

# **Cervical Cancer Screening & Follow-up**

#### BCCEDP CERVICAL SCREENING POLICY

#### **Effective 10/1/2001**

The VABCCEDP will provide funding for annual Pap tests for program eligible women until they have had **three MDE documented**, **consecutive**, **negative or benign Pap tests within a five-year period (60 months)**. Thereafter, the screening interval for these women will be once every **three** years.

Funds may also be used to reimburse for screening services on an **annual** basis if a woman receives an **abnormal** screening result after three, consecutive, annual Pap tests with normal/benign findings. Annual screening would resume until three, consecutive, annual Pap tests with normal/benign findings within five years are received. If three normal/benign results within a five-year period have been or are currently documented in the program's MDEs, VABCCEDP-funds may only be used to reimburse for Pap tests once every three years.

NOTE: Annual Pap test is defined as a Pap test performed within 12-18 months of the previous Pap test. This policy does not eliminate the need for annual pelvic examinations, CBE's and mammograms.

#### Sample Scenario #1

A woman receives her first Pap smear with the VABCCEDP on October 1, 1994. The Pap smear provides a result of "Negative". The clinician recommends that the patient return for another Pap smear in a year.

The woman returns on November 10, 1995 for a second Pap smear in the VABCCEDP. The Pap smear provides a result of "Infection". The clinician recommends that the patient return for another Pap smear in a year.

The woman returns on December 1, 1996 for a third Pap smear in the VABCCEDP. The Pap smear provides a result of "Negative". The clinician explains to the woman that she has now received three consecutive annual "Negative" Pap smears and the good news is that she does not need another Pap smear for three years.

The woman returns on November 1, 1999 for a fourth Pap smear in the VABCCEDP. The Pap smear results in a "Negative" finding. The clinician recommends that the woman return for another Pap smear in three years.

#### **Graphical Display of Scenario #1**

Pap 1	Pap 2	Pap 3	Pap 4	Pap 5
Negative	Infection	Negative	Negative	Schedule
10/01/94	11/10/95	12/1/96	11/1/99	11/02

#### Sample Scenario #2

A woman receives her first Pap smear with the VABCCEDP on August 15, 1995. The Pap smear provides a result of "Negative". The clinician recommends that the patient return for another Pap smear in a year.

The woman returns on December 10, 1996 for a second Pap smear in the VABCCEDP. The Pap smear provides a result of "Infection". The clinician recommends that the patient return for another Pap smear in a year.

The woman returns on February 1, 1998 for a third Pap smear in the VABCCEDP. The Pap smear provides a result of "Low Grade SIL". The clinician recommends a colposcopy w/biopsy to evaluate the lesion. The colposcopy w/biopsy returns as "Benign". The clinician then recommends that the woman return for a Pap smear in 6 months.

The woman returns on August 15, 1998 for a fourth Pap smear in the VABCCEDP. The Pap smear returns with a result of "Negative". The clinician recommends that the patient return for another Pap smear in a year.

The woman returns on August 1, 1999 for a fifth Pap smear in the VABCCEDP. The Pap smear returns with a result of "Negative". The clinician recommends that the patient return for another Pap smear in a year.

The woman returns on September 1, 2000 for a sixth Pap smear in the VABCCEDP. The Pap smear returns with a result of "Negative". The clinician explains to the woman that she has now received 3 consecutive annual "Negative" Pap smears and the good news is that she does not need another Pap smear for 3 years. The clinician recommends that the woman return in 3 years for another Pap smear.

#### **Graphical Display of Scenario #2**

Pap 1	Pap 2	Pap 3/Biopsy	Pap 4	Pap 5	Pap 6	Pap 7
Negative	Infection	LSIL/Benign	Negative	Negative	Negative	Schedule
8/15/95	12/10/96	2/1/98	8/15/98	8/1/99	9/1/00	9/03

#### Sample Scenario #3

A woman receives her first Pap smear with the VABCCEDP on August 15, 1996. The Pap smear provides a result of "Negative". The clinician recommends that the patient return for another Pap smear in a year.

The woman is no longer eligible to receive screening through the VABCCEDP. However, she visits a non-VABCCEDP provider on December 10, 1997 for a second Pap smear. The Pap smear provides a result of "Infection". The non-VABCCEDP provider recommends that she return for another Pap smear in a year.

The woman has lost her job and once again meets the eligibility requirements to receive services through the VABCCEDP. She returns on February 1, 1999 for a second Pap smear in the VABCCEDP. The Pap smear provides a result of "Negative". If the clinician knows the Pap smear result from the previous year, then he informs the woman that she has had 3 consecutive annual "Negative" Pap smears and that she does not need another Pap smear for 3 years. On the other hand, if the clinician does not have the result from the non-VABCCEDP provider, then he may recommend a Pap smear in a year.

The Clinician Knows the Result of the Non-VABCCEDP Pap smear:

Pap 1	Pap 2 (non- VABCCEDP provider)	Pap 3	Pap 4
Negative	Infection	Negative	Schedule
8/15/96	12/10/97	2/1/99	3/15/02

#### The Clinician Does Not have the Result from the Non-VABCCEDP Provider

Pap 1	Pap 2 (non- VABCCEDP provider)	Pap 3	Pap 4	Pap 5
Negative	Unknown	Negative	Negative	Schedule
8/15/96	12/10/97	2/1/99	3/15/00	4/03

#### **ASCCP GUIDELINES**

ALGORITHMS FROM THE CONSENSUS GUIDELINES FOR THE MANAGEMENT OF WOMEN WITH CERVICAL CYTOLOGICAL ABNORMALITIES

The American Society for Colposcopy and Cervical Pathology (ASCCP) sponsored a national consensus conference in Bethesda, Maryland on September 6-8, 2001. The conference was attended by 29 national and international health organizations, professional societies, and federal agencies. These algorithms provide a summary of the recommendations for managing women with cytological abnormalities. A description of the evidence supporting the guidelines and the guidelines themselves have previously been published in JAMA (2002;287:2120-2129). IT IS STRONGLY RECOMMENDED THAT THE HEALTHCARE PROVIDER REVIEWING AND UTILIZING THESE ALGORITHMS READ THE GUIDELINES.<sup>1</sup>

A copy of the algorithms can be found in Appendix A and can also be located at the following website: www.asccp.org

<sup>&</sup>lt;sup>1</sup> Algorithms from the Consensus Guidelines for the Management of Women with Cervical Cytological Abnormalities

#### **HPV TESTING**

HPV testing is a reimbursable procedure if used in follow-up of an ASC-US result from the screening examination and it is the **preferred** method for follow-up of ASC-US. However, it is just one of three fully acceptable methods of management following a Pap test reported as ASC-US

The three acceptable methods of management are as follows:

- 1. Immediate colposcopy for all women with ASC-US
- 2. Repeat the Pap test twice at 4-6 month intervals; if either test is positive for ASC-US, perform a colposcopy.
- 3. HPV DNA testing for **high risk** types of HPV only. If the result is positive, perform a colposcopy. If the result is negative, perform a Pap smear in 12 months.

The only product currently approved by the FDA for HPV testing is the Hybrid Capture II (HCII) from Digene.

### Data

Vers. 07/03



### **ELIGIBILITY FORM**

Last Name	First Name	Middle Initial				
Social Security No	Birth Date//	Age				
Address						
CityCc	ounty	StateZip				
Home Phone ( ) Wor	rk Phone ( )	Best Time to Call				
1. Are you Spanish, Hispanic, or Latina	a?	No Don't know				
2. Do you describe yourself as: (check White Black/African American American Indian/Alaskan Native	_ Asian (or Indian)  Nat	tive Hawaiian or Pacific Islander				
3. What language do you speak every d	lay?					
4. What is your household income before	ore taxes? \$	Monthly Yearly				
5. How many people live on this incom	ne? (include yourself)					
6. Do you have: Medicare? Yes	No Medicaid? Yes N	No Private Insurance? Yes No				
→If you have insurance, did you pay all	of your insurance deductible f	for this year? Yes No				
7. Have you ever had a Pap test? \( \subseteq Y	es No					
→If YES, when was your last Pap test?	(month/year)					
or More than 5 years ago Don'	t know					
8. Have you ever had a mammogram?	☐Yes ☐ No					
→If YES, when was your last mammog						
or	't know					
Office Use Only						
Administrative Site:	Enrollment Date: _	//				
Enrollment Site:	Case Manager:					
Referred By (If Applicable): CLOW Sisters Network Other:						
Client Status: Active – check one: New Patient Rescreen Client ID						
Inactive due to: (list reason)	Eff	f. Date				



### Breast and Cervical Cancer Early Detection Program Virginia Department of Health

#### **SCREENING ENCOUNTER FORM**

ADI	AIN Site	DMIN Site Cycle Start Date		□ New Patient □ FU □ Rescreen Client ID				
Las	t Name	First Name		MI	SSN (or	alien ID):		
		2 22 20 2 1 102 22 2			, i	,		
	CLINICAL BREAST EXA	AM (CBE)		CERVICAL S	CREEN	ING		
1.	Does the patient have breast symptom	oms? □Yes □ No	12.	Did the patient have a Pap te	st ( <b>8814</b>	1)? • Yes • No		
2.	Did the patient have a CBE? □Ye	s 🗖 No	13. Date of Pap test/ (mm/dd/yyyy)					
3. 4. 5. 6. 8.	CBE Date// What were the CBE results? Normal or Benign Abnormal, suspicious for cance evaluation needed Not needed, previously performed (included) Was the CBE paid by BCCEDP?  MAMMOGRAM Did the patient have a mammogram Screening (76092) Diagnosti Date of mammogram/ What were the mammogram results Negative Benign finding Probably benign Suspicious abnormality Highly suggestive of malignam Assessment incomplete Unsatisfactory, film cannot be Mammogram Result pending Result unknown, presumed abnormal by BCCEDP Not needed or previously performed by BCCEDP Needed but not performed (incomplete) Was the mammogram paid by BCCI Where was the mammogram performance. Radiology Facility:	er – diagnostic  med, normal CBE les refused CBE)  1 Yes 2 No  1  1? c (76091) No  / (mm/dd/yyyy)  s?  cy interpreted—repeat  normal, from other  ormed with services not cludes refused)  EDP? 2 Yes No  med?	14. 15. 16. 17. 18. 19.	If so, what were the Pap test  Negative (for intraepithe ASC-US ASC-US ASC-H LGSIL HGSIL Squamous cell carcinom Abnormal Glandular Cell Other result: Result pending Result unknown, presum program funded source Not needed or done prevanot paid by BCCEDP Needed but not performed Cervix present? Yes (Cell Specimen Type: Convention Specimen adequacy? Satisfactory Unsatisfact Was the Pap test paid by BCC Where was the Pap test performance Facility/Clinic: HPV Test Result? Positiv HPV Test Date:// Was the patient referred for cell	results?  clial lesion  a lls  ned abnoriously electrical)  onal  ctory: rectory: re	on or malignancy)  ormal, from non- elsewhere with services ades refused)  No (Vaginal)  Liquid-based Other  epeat Pap  Yes No  egative Not Done (mm/dd/yyyy)		
11.	Was the patient referred for breast d  ☐Yes ☐ No							
F	Form Completed By (Signature) Date							



#### Breast and Cervical Cancer Early Detection Program Virginia Department of Health

#### BREAST DIAGNOSTIC ENCOUNTER FORM

Last Name		First Nai	me	MI	SSN (or alien ID):	Cycle Start Date
			DIAGNOS	TIC PROCEDUI	RES	
1a. Additional Mammographic views	2. Ult <b>76645</b>	rasound	3. Repeat Breast Exam/Surgical Consult (99244)	4. Fine Needl Cyst Aspiration Result (88170	le / 5. Breast Biopsy on Interpretation/-	6. Add'l. Diagnostic Procedure(s): (check all that apply)
☐ Yes ☐ No ☐ Refused	☐ Yes ☐ No ☐ Refus	sed	☐ Yes☐ No☐ Refused	☐ Yes* ☐ No ☐ Refused	☐ Yes* ☐ No ☐ Refused	□ Stereotactic guided breast biopsy, needle placement (76095) □ Mammography guided needle placement (76096) □ Ultrasonic guidance for cyst
1b. Diagnostic Mammogram ☐ Unilateral 76090 ☐ Bilateral 76091				* Report add'l. procedure(s) do w/ breast FNA i #6	w/ breast biopsy in #6	aspiration (76938)
Date of Procedure	Date of P	rocedure/	Date of Procedure	Date of Procedure		☐ Cyst aspiration, additional (19001) ☐ FNA without imaging
Results:  Negative Benign findings Probably benign Suspicious abnormality Highly suggestive of malignancy Assessment incomplete	Results:  Nega Benign Cysti Solid	tive/-	Results:  Normal Abnormal Other benign findings	Results:  Normal Abnormal Indeterminate	Results:  Benign Malignant  Indeterminate	(10021)  ☐ FNA with imaging (10022) ☐ Needle core biopsy, without guidance (19100) ☐ Incisional biopsy (19101) ☐ Excision of cyst (19120) ☐ Excision of lesion identified by pre-op placement of radiological marker (19125)
Funding Source:  CDC Other	Funding  CDC  Other		Funding Source:  CDC Other	Funding Source  CDC Other	Funding Source: CDC Other	□ Excision of lesion identified by pre-op placement of radiological marker, additional (19126) □ Pre-op placement of needle localization wire (19290) □ Other: □ CPT Code □ □
DIA	GNOSTI	C EVALUA	ATION STATUS		BREAST CANC	ER TREATMENT STATUS
8. What is the status of the final diagnosis?  □ Work-up complete (complete Q. 8 & 9)  □ Work-up pending □ Patient lost to follow-up – Date: □ Work-up refused – Date: □ Work-up refused = Date:  8. Date of Final Diagnosis		s? 9)  Invas  M Stage I  M Stage II  M Stage III  M Stage IV  nmary Local  nmary ional  nmary Distant	ive tumor size?  1) to ≤ 1 cm  >1 to ≤ 2 cm  >2 to ≤ 5 cm  > 5 cm  Unknown	O What cance Treatment started: Treatment pending Patient lost to follo Treatment refused Treatment not need Treatment not need  12. What type of treatmapply) Mastectomy Lumpectomy Chemotherapy Radiation Hormonal Other:	eat is the treatment status for breast eer?	
Form Completed By (Signature) Date						



### Breast and Cervical Cancer Early Detection Program Virginia Department of Health

#### CERVICAL DIAGNOSTIC ENCOUNTER FORM

Last Name	First Name	MI SSN (or alien ID):	Cycle Start Date
1. Colposcopy, only 57452  Yes *  No Refused  * if done w/ ECC, report CPT co	2. Colposcopy w/ Biopsy 57  □ Yes* □ No □ Refused	□ Yes □ No □ Refused	4. Other (e.g., LEEP, pelvic ultrasound, endometrial biopsy)  CPT Code
Date of Procedure	Date of Procedure	Date of Procedure	Date of Procedure
//	//	//	/
Results:  Normal Abnormal Indeterminate  Funding Source:	Results:  Normal/Benign  Malignant  Indeterminate  Funding Source:	Results:  Normal/Benign  Malignant  Indeterminate  Funding Source:	Results:  Normal/Benign  Malignant Indeterminate  Funding Source:
□ CDC □ Other	□ CDC □ Other	□ CDC □ Other	□ CDC □ Other
DIAGNOSTIC E	EVALUATION STATUS	CERVICAL CANCER	TREATMENT STATUS
7. Final diagnosis.  Normal/Benign Reaction/In  HPV/Condylomata/Atypia.  CIN I/Mild Dysplasia (biop  CIN II/Moderate Dysplasia/C  diagnosis)  Invasive Cervical Carcinor  Other:  Low grade SIL  High grade SIL  8. Cancer Stage:  1: Stage I 4: S  2:Stage II 5:S	pate: / / flammation/Infection (ASCUS by diagnosis)	☐ Treatment pending ☐ Patient lost to follow-up — ☐ Treatment refused — Date: ☐ Treatment not needed  10. What type of treatment wa ☐ Cryosurgery ☐ Radiation ☐ Chemotherapy ☐ Hysterectomy ☐ LEEP ☐ ECC ☐ Other ☐ Other ☐ Yes ☐ No	Date: as recommended? (check all that apply)
Form Completed By (Signa	ture)	Date	

Vers. 07/03



### Breast and Cervical Cancer Early Detection Program Virginia Department of Health

#### ADDITIONAL COMMENT FORM (OPTIONAL)

Last Name	First Name	MII	SSN (or Alien ID)	Cycle Start Date		
Additional CommentsPlease	e date and sign note(s):					
Waiver Statement:						
I certify that I have been advised as to the need for follow-up medical evaluation or treatment and the consequences of not getting this evaluation or treatment. I have decided to exercise my right to refuse any type of follow-up medical evaluation or treatment.						
Signature		Date:	//			
Witness Signature		Date:	//_			
witness Signature						

### **Recommended Forms**

Vers. 07/03



### Breast and Cervical Cancer Early Detection Program Virginia Department of Health

#### CLIENT SATISFACTION QUESTIONNAIRE

We wish to improve our services and learn your reaction to the clinic and its staff. In order to make improvements to better serve you and other women who are enrolled in the *Every Woman's Life* Program, we need your help. Please take a few minutes to answer the following questions. Please answer honestly. This information will be kept confidential. We will not identify you by name. Thank you for your time and help.

		Where Pap was performed	Where Mammogram was
			performed
1.	How much time went by between when you	☐ 1 week	☐ 1 week
	called to make an appointment and the	□ 2 weeks	☐ 2 weeks
	scheduled visit date?	□ 3 weeks	□ 3 weeks
		□ 4 weeks	□ 4 weeks
		☐ More than 4 weeks	■ More than 4 weeks
2.	Were the clinic hours:	□ Convenient	□ Convenient
		□ Not Convenient	□ Not Convenient
3.	Was the front desk staff pleasant and helpful?	☐ Yes ☐ No	☐ Yes ☐ No
4.	Did the staff know about the Every Woman's	□Yes	□Yes
	Life Program?	□ No	□ No
	-	□ Don't know	☐ Don't know
5.	How much time did you spend in the waiting	☐ <10 mins	☐ <10 mins
	room before going into an exam room was:	☐ 10-20 mins	☐ 10-20 mins
		□ 30 mins	□ 30 mins
		□ > 30 mins	□ > 30 mins
6.	After going into the exam room, how much time	☐ <10 mins	☐ <10 mins
	went by before a nurse or doctor saw you?	☐ 10-20 mins	☐ 10-20 mins
		□ 30 mins	□ 30 mins
		□ > 30 mins	□ > 30 mins
7.	Did you have privacy during your interview or	☐ Yes ☐ No	☐ Yes ☐ No
	exam?		
8.	Were the results of your visit discussed with	☐ Yes	☐ Yes
	you?	□ No	□ No
		□ Results not back yet	Results not back yet
9.	How well did the information that you were	☐ Poor	☐ Poor
	given ease your fears?	□ Fair	□ Fair
		☐ Good	☐ Good
		□ Excellent	□ Excellent
		Outstanding	Outstanding
10.	Were all your questions and concerns	☐ Yes ☐ No	☐ Yes ☐ No
	answered?		
11.	Were you taught how to examine your own	☐ Yes	
	breasts at your Pap smear visit?	□ No	Not Applicable
		□ Already knew	
12.	Were you given information to take home with	☐ Yes ☐ No	☐ Yes ☐ No
	you?		
13.	Did the office staff help you make any other	☐ Yes ☐ No	☐ Yes ☐ No
	appointments that you needed?	□ No more needed	■ No more needed

14. How satisfied were you with th		1		dissatisfied				
service you received at this fac	cility?		ifferent/ Mil		sfied	fied Indifferent/ Mildly dissatisfie  Mostly satisfied		
		☐ Mostly☐ Very s		u			ery satisfied	
15. Overall, were you treated	Nursing		poor	☐ Fair	□G		□ excellent	□ outstanding
properly and with respect by the following staff members	Doctors		□ poor	□ Fair	□G	ood	□ excellent	□ outstanding
where you had the <b>Pap Smear</b> done:	Radiolo Staff:	gу	□ poor	☐ Fair	□G	ood	□ excellent	□ outstanding
	Admissi	ions	□ poor	☐ Fair	□G	ood	□ excellent	□ outstanding
16. Overall, were you treated	Staff: Nursing	staff:	□ poor	☐ Fair	□G	ood	□ excellent	outstanding
properly and with respect by the following staff members	Doctors	:	□ poor	☐ Fair	□G	ood	□ excellent	□ outstanding
where you had the <b>Mammogram</b> done:	Radiolo Staff:	gy	□ poor	☐ Fair	□G	ood	□ excellent	□ outstanding
	Admissi Staff:	ions	□ poor	☐ Fair	□G	ood	□ excellent	□ outstanding
Please answer the following quest	•	ut the E	very Woma	ın's Life Pı	rogran	n in G	eneral	I
17. To what extent has the <i>Every</i>	Woman's	Life	☐ Non	e				
program met your needs?			☐ Mos	☐ Only a few☐ Most				
18. If you were to seek help again	would v	OU COM	□ Alm	ost all nitely not				
back to the Every Woman's Li				't think so				
	Ü			☐ Think so				
19. If a friend were in need of simi	lar holo	would	☐ Defi					
you recommend our program		would		☐ Definitely not☐ Don't think so				
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			☐ Thir	☐ Think so				
			☐ Defi	nitely				
Additional Comments:								
Additional Comments.								
Interview Date: Interviewer:								



# Virginia Breast & Cervical Cancer Early Detection Program DOCUMENTATION CHECKLIST

Patient Name: \_\_\_\_\_\_BCCEDP Client ID: \_\_\_\_\_

Document the date in the appropriate box or write in "N/A" if not applicable. Initial each entry.								
	Date Completed/ Initials	Date Submitted/ Initials	Date Completed/ Initials	Date Submitted/ Initials	Date Completed/ Initials	Date Submitted/ Initials		
Eligibility Determined								
Signed Informed Consent/Medical Release Form (annually) Screening Encounter Form								
Screening Encounter Form								
Breast Cancer Diagnostic Encounter Form*								
Cervical Cancer Diagnostic Encounter Form*								
Additional Comments Form**								
Other								
Other								
Other								
Initials								
*To be completed if Diagno	ostic Follow-U	p is indicated	l. ** Optiona	1	<u> </u>			
Initials Signature & Credentials Initials Signature & Credentials								



# Virginia Breast & Cervical Cancer Early Detection Program PATIENT EDUCATION CHECKLIST

Patient N	Name:BCCEDP Client ID:						
	nt the date and initial indicate in the date and initial in the bottom of		-		n/a'' if not a	pplicable.	
		Date Completed	Date Completed	Date Completed	Date Completed	Date Completed	
		Initials	Initials	Initials	Initials	Initials	
Basic ana	atomy & physiology						
Risk Fac	tors						
Current guideline	recommended es						
Benefits	of early detection						
BSE pro	cedures						
Importar self-exan	nce of monthly breast						
Clinical l	Breast & Pelvic Exam						
Mammo	graphy procedures						
	nce of regular breast ical cancer screening						
Exit educ	cation/instructions						
Other							
Other							
Initials Signature & Credentials		lentials	Initials	Signa	ature & Cre	dentials	
	1		1	1			



Other Other

### Virginia Breast & Cervical Cancer Early Detection Program

Patient Name:		BCCEDP Client II	):			
Document the date and initial in the appropriate box or write in ''N/A'' if not applicable. Initial and sign at the bottom of the page with your credentials.						
	Date Completed/ Initials	Date Completed/ Initials	Date Completed/ Initials			
Screen Appointment Scheduled						
Pre-Appointment Instructions						
Directions to Provider Site						
Transportation Assistance						
Clinical Breast Exam						
Pap Smear DOS						
Pap Report Received						
Patient Notified of Pap Result						
Mammogram DOS						
Mam Report Received						
Patient Notified of Mam Results						
Other						
Other						
Breast F/U Due						
Breast F/U Appt. Date						
Cervical F/U Due						
Cervical F/U Appt. Date						
Annual Mam Due						
Annual Pap Due						
Rescreen: 1st Reminder Sent						
Rescreen: 2 <sup>nd</sup> Reminder Sent						
Rescreen: 3 <sup>rd</sup> Reminder (Phone)						
Other						

Initials	Signature & Credentials	<b>Initials</b>	Signature & Credentials



### Virginia Breast & Cervical Cancer Early Detection Program

## PROGRESS NOTE CASE MANAGEMENT/DOCUMENTATION

Patient Name:		BCCEDP Client ID:	BCCEDP Client ID:		
DATE	NOTES	SIGNATUR	 E		

### **Virginia Breast & Cervical Cancer Early Detection Program**

### SPREADSHEET FOR WOMEN ENROLLED IN BCCEDP

	А	В	С	D	Е	F	G	Н	I	J	K	L	М	N	0	Р	Q	R	S
1	Spreadsheet fo	or Women En	rolled in BCCE	DP															
2							DOS		Payor		Pt	DOS		Payor		Pt	Forms to	DOE	Re-Screen
3	Last Name	First Name	SS#	R	Α	Pt#	Mammo	Facility	Mamm	Result	Notified	Pap	Facility	Pap	Result	Notified	Billing		Due
4	Doe	Jane	555-55-5555	В	53	999999	05/19/1999	Memorial	cdc	neg	05/25/1999	05/03/1999	PO	cdc	neg	05/10/1999	06/01/1999	05/03/1999	May, 2000
5	Brown	Mary	999-99-9999	W	52	888888	06/15/1999	St. Mary's	cdc	ABN	06/16/1999	06/01/1999	СН	cdc	neg	06/10/1999	07/01/1999	06/01/1999	Jun, 2000
6	Smith	Susie	888-88-888	Н	60	777777	07/07/1999	St. Luke's	Komen	neg	07/08/1999	07/01/1999	СН	cdc	HGSIL	07/10/1999	08/01/1999	07/01/1999	Jul, 2000
7																			
8																			
9																			
10																			

## **Quality Assurance**

#### **BCCEDP AUDIT GUIDELINES**

Listed below are the categories that will be covered during the audit process. The audit categories contain an explanation of what the auditor is assessing.

#### **GENERAL REQUIREMENTS**

It is expected that the case manager will maintain copies of all mammograms, Pap smears, pelvic examinations, and CBE clinical examination notes. In addition, the case manager will maintain copies of all work-up reports including, but not limited to, surgical & GYN consults, fine needle aspirations, biopsies, colposcopies, and ultrasounds.

<u>Recruitment/Target Enrollment</u>: All administrative provider sites are assigned a target number of women to screen/rescreen within a given fiscal year. If the target is not achieved, points will be deducted.

<u>Interpreter Services</u>: It is the expectation that interpreter services will be available if needed.

<u>Patient Tracking/Rescreen Reminder System</u>: A tracking system must be in place. For example, a tracking system can be maintained through a computer program, tickler system, or spreadsheet. Verbal reminders to patients must be documented on a progress note. Copies of written reminders must be placed in the patient's record.

#### **RECORD REVIEW**

At the time of the audit, the case manager will provide records for the auditor to review. In most cases, the case manager will receive a list of names prior to the arrival of the auditor. However, the auditor maintains the right to petition additional records at the time of the audit.

<u>Compliance with Breast Cancer Screening Algorithm</u>: It is expected that the *Timeliness & Adequacy of Breast Cancer Screening Algorithm* will be followed. A copy of the algorithm can be found in the BCCEDP Orientation Manual.

Compliance with Cervical Cancer Screening Algorithm: It is expected that the Algorithms from the Consensus Guidelines for the Management of Women With Cervical Cytological Abnormalities will be followed. These algorithms were established by the American Society For Colposcopy and Cervical Pathology. A copy can be found on their web site at <a href="https://www.asccp.org">www.asccp.org</a>.

<u>Appropriate Referrals</u>: A system must be in place to refer women for medical problems unrelated to the breast and cervix.

<u>Signed Consent with Date</u>: The consent form must be signed and dated annually. The date of enrollment is the date that the patient was originally enrolled in the program and remains fixed over time.

Version 3/13/03 52

<u>Patient Notification of Abnormal Pap Results</u>: The patient shall be notified of her abnormal result within five business days of the receipt of the result by the administrative provider site. Documentation of the notification must be present in the record.

<u>Patient Notification of Normal Pap Results</u>: The patient shall be notified of her normal result within 10 business days of the receipt of the result by the administrative provider site. Documentation of the notification must be present in the record.

<u>Patient Notification of Abnormal Mammogram Results</u>: The patient shall be notified within 5 business days of the receipt of the result by the administrative provider site. Documentation of the notification must be present in the record. (Note: The patient shall receive notification of normal results by the mammography provider)

<u>Ultrasound Approval Obtained</u>: A signed ultrasound approval form must be present in the chart if the patient receives a breast ultrasound. Approval may be obtained after the procedure is performed. A copy of the form can be found in the Orientation Manual.

<u>Patient Education Protocol</u>: The case manager must be able to produce a <u>written</u> protocol for patient education at the time of the audit. The parameters that must be covered are present on the Patient Education Checklist in the BCCEDP Orientation Manual.

<u>Missed Appointment F/U</u>: If a patient fails to show for an appointment, there must be documentation present on a progress note of efforts to reach her to re-schedule. Three attempts to contact the patient on three separate days should be performed. If these three attempts are unsuccessful in reaching the patient, a certified letter should be sent.

If three appointments are missed (i.e., "no shows"), the case manager reserves the right to discharge the patient from the BCCEDP. A **brief synopsis** indicating why a patient is refusing should be present on the *Additional Comments* form and submitted to the central office.

<u>Contacts with Patient Documented in Medical Record</u>: Verbal communication with the patient must be documented on a progress note. All documentation in the progress notes must be dated and signed with credentials. Copies of written communication must be present in the record.

Appropriate Medicaid Enrollment: A women referred to Medicaid under the Breast and Cervical Cancer Prevention and Treatment Act must be a BCCEDP enrollee and must have received screening or diagnostic services through the program. She must have been diagnosed with breast or cervical cancer or a pre-cancerous condition related to the breast or cervix. She must be deemed in need of treatment for her condition by a clinician. Treatment may be palliative as well as curative.

Version 3/13/03 53

<u>BCCPTA Application Completed & Signed</u>: The form must be filled out completely and sent to the Department of Social Services in the county or city where the patient resides. A copy must be sent to the BCCEDP Central Office.

Medicaid Eligibility Ends When Treatment Ends: A letter must be sent to the patient's physician indicating that her eligibility for Medicaid ends when her treatment has ended. A copy of the letter must be given to the patient with documentation that she has been informed.

<u>Pap Result Correctly Coded</u>: The auditor will compare the Pap smear report with the data that has been reported to verify concurrence.

<u>Mammography Result Correctly Coded</u>: The auditor will compare the mammogram report with the data that has been reported to verify concurrence.

<u>Staging Information Correctly Coded</u>: This information can be best obtained from the treating physician. The Cancer Registry will not be able to provide you with this information in a timely manner.

<u>Adherence to Policies & Procedures</u>: It is expected that the administrative provider sites will comply with all new written policies.

#### **DATA PERFORMANCE INDICATORS:**

The data is obtained from the Data Manager's database in the BCCEDP Central Office. This information is ultimately communicated to the Centers for Disease Control and Prevention (CDC). The performance indicators are one of the standards by which the VABCCEDP is evaluated by the CDC.

Version 3/13/03 54

## VIRGINIA BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAM CLINICAL RECORD & DATA SUMMARY

#### **AUDIT REPORT**

Administrative Provider Site:	
Subcontractor Sites:	
Case Manager(s):	
Coordinator(s):	
Auditor:	
Audit Date:	
# Charts Reviewed:	
Auditor's Signature	Date

#### **General Requirements (10 Points)**

Category	# Points	See Commentary	Points Achieved
	Possible		
Recruitment/Target	5		
Enrollment			
<b>Interpreter Services</b>	1		
Patient Tracking/Rescreen	4		
Reminder System			
<b>Total Points Achieved</b>	10		

Version 09/02 55

### **Record Review (42 Points)**

Category	# Points Possible	See Commentary	# Points Achieved
<b>Compliance with Breast Cancer</b>	4		1101110 / 002
Screening Algorithm			
Compliance with Cervical Cancer	4		
Screening Algorithm			
Appropriate Referrals	2		
Signed Consent with Date	2		
(annually)			
Patient Notification of Abnormal	2		
Pap Results within 5 working days			
Patient Notification of Normal Pap	2		
Results within 10 working days			
Patient Notification of Abnormal	2		
Mammogram Results within 5			
Working Days			
Ultrasound Approval Obtained	1		
<b>Patient Education Protocol</b>	1		
Missed Appointment F/U	2		
<b>Contacts with Patient Documented</b>	3		
in Medical Record			
Appropriate Medicaid Enrollment	3		
BCCPTA Application completed &	2		
signed			
Medicaid Eligibility Ends When	2		
Treatment Ends (Letter)			
Pap Result Correctly Coded	2		
Mammography Result Correctly	2		
Coded			
Staging Information Correctly	1		
Coded			
Adherence to policies & procedures	5		
as outlined in the Medical Protocol			
Manual & memoranda generated			
by the VABCCEDP			
<b>Total Points Achieved</b>	42		

#### **Commentary**

Version 09/02 56

Category	# Points Possible	Compliance Rate (%)	# Points* Achieved
Time Between Mammography DOS & Reception of	4	14466 (70)	11cme vea
Results (GOAL: >= 75% within 21 days)			
Time Between Pap Test DOS & Reception of Results	4		
(GOAL: >= 75% within 21 days)			
% Never/Rarely Screened for cervical cancer prior to	4		
enrollment (initial Pap only) (GOAL: >= 20%)			
Rescreen Rate: within 18 mos. of initial screening	4		
(GOAL: >= 50%)			
CERVICAL FOLLOW-UP			
Completion of Workup to Final Diagnosis (GOAL: >=	4		
90% of cases) <sup>1</sup>			
Time from Initial Screening to Final Diagnosis (GOAL:	4		
$>=75\%$ within $60 \text{ days})^2$			
Initiation of Treatment (GOAL: >= 90% of cases) <sup>3</sup>	4		
Time from Final Diagnosis to Treatment (GOAL: >=	4		
80% within 60 days) <sup>4</sup>			
BREAST FOLLOW-UP			
Completion of Workup to a Final Diagnosis (GOAL:	4		
$>= 90\% \text{ of cases})^5$			
Time from Initial Screening to Final Diagnosis (GOAL:	4		
>=75% within 60 days) <sup>6</sup>			
<b>Initiation of Treatment (GOAL: &gt;= 90% of cases)</b> <sup>7</sup>	4		
Breast Abnormal Results: Time from Final Diagnosis	4		
to Treatment (GOAL: >= 80% within 60 days)			
TOTAL POINTS ACHIEVED	48		

Note: Performance measures were based on data obtained and entered by \_\_\_\_\_\_.

**Data Compliance Rate\*** 

Percentage	# Points
At or above Goal	4
-3% of Goal	3
-4% to -6% of Goal	2
-7% to -10% of Goal	1
More than 10% below Goal	0

Version 09/02

57

<sup>&</sup>lt;sup>1</sup> Applies to HGSIL and Squamous cell carcinoma Pap test results

<sup>&</sup>lt;sup>2</sup> Applies to HGSIL and Squamous cell carcinoma Pap test results.

<sup>&</sup>lt;sup>3</sup> CIN II, CIN III, CIS and invasive cervical cancer only.

<sup>&</sup>lt;sup>4</sup> CIN II, CIN III, CIS and invasive cervical cancer only.

<sup>&</sup>lt;sup>5</sup> Applies to cases of abnormal CBE and/or mammography results.

<sup>&</sup>lt;sup>6</sup> Applies to abnormal mammogram results only: Assessment Incomplete (BIRADS 0), Suspicious Abnormality (BIRADS 4), and Highly Suggestive of Malignancy (BIRADS 5).

<sup>&</sup>lt;sup>7</sup> Breast cancer in situ and invasive cases only.

<sup>&</sup>lt;sup>8</sup> Breast cancer in situ and invasive cases only.

#### **Summary**

Category	<b>Total Points Possible</b>	<b>Total Points Achieved</b>
General	10	
<b>Record Review</b>	42	
Performance	48	
Indicators		
<b>Grand Total</b>	100	

#### **Rating**

Points	Rating
95-100	Excellent
90-94	Very Good
80-89	Good
70-79	Unsatisfactory
< 70	Critical Failure

Version 09/02 58

#### DOCUMENTATION OF PATIENT EDUCATION

Each provider site must have **in writing** an education protocol that is consistent with the BCCEDP protocol for education. The protocol dictates that the following items must be covered:

- Basic anatomy and physiology (breast & cervix)
- Risk Factors for breast and cervical cancer
- Current recommended guidelines for screening
- Benefits of early detection
- Breast self-exam procedures
- Importance of monthly breast self-exams
- Clinical breast and pelvic exam procedures
- Mammography procedures
- Importance of regular breast and cervical cancer screening
- Exit education/instructions

The above items can be covered verbally, in writing (handouts/brochures), or via video.

#### PERFORMANCE INDICATORS

- 1. At least 75% of the mammograms provided to NBCCEDP eligible women will be 50 years of age and older. The Virginia standard is 80%.
- 2. The number of days between the date of service of an abnormal Pap test and the date of final diagnosis shall not exceed 60 days.

3a. The number of days between an abnormal Pap test and the date of final diagnosis shall not exceed 60 days.

3b.The number of days between an abnormal mammogram and the date of final diagnosis shall not exceed 60 days.

- 4. The number of days between the date of final diagnosis of cervical cancer and the start of treatment shall not exceed 60 days.
- 5. The number of days between the date of final diagnosis of breast cancer and the start of treatment shall not exceed 60 days.
- 6. At least 90% percent of abnormal Pap tests (i.e., HSIL, squamous cancer) will have work-up completed to a final diagnosis recorded on the Cervical Diagnostic Encounter Form.
- 7. At least 90% of abnormal mammograms and/or CBEs will have completed work-up to a final diagnosis recorded on the Breast Diagnostic Encounter Form.
- 8. At least 90% of cases of diagnosed cervical cancer will have treatment initiated or be reported as treatment "refused" or patient "lost to follow-up" on the Cervical Diagnostic Encounter Form.
- 9. At least 90% of cases of diagnosed breast cancer will have treatment initiated or be reported as treatment "refused" or patient "lost to follow-up" on the Breast Diagnostic Encounter Form.
- 10. All sites shall have a reminder system in place to notify women when their annual rescreens are due. The goal is to achieve a re-screen rate of 75%.

- 11. At least 20% of the women enrolled should have never or rarely been screened for cervical cancer prior to enrollment. Rarely is defined as five or more years.
- 12. Emphasis should be placed on recruiting ethnic and racial minority women.

### Medicaid

## BCCEDP POLICY RELATED TO MEDICAID TREATMENT REIMBURSEMENT

#### **ELIGIBILITY**

Women who are screened through the Virginia BCCEDP, diagnosed with cancer or a pre-cancerous condition and certified as needing treatment by a BCCEDP Provider may be eligible for payment of that treatment by Medicaid under the Breast and Cervical Cancer Prevention and Treatment Act (BCCPTA). See section entitled: Women Who Are Not Eligible For Medicaid Under BCCPTA. The BCCEDP provider will seek pro bono or reduced cost treatment services for any women ineligible for Medicaid under the BCCPTA.

Treatment is defined as all forms of treatment prescribed by a physician, including palliative care.

If a BCCEDP eligible woman is seen by a health professional at any non-BCCEDP health care provider site because of a 'lump' or symptom that is suspicious for cancer, she is eligible to be referred to a BCCEDP Provider to be <u>screened and diagnosed</u> for breast and/or cervical cancer. If the woman is then diagnosed with breast or cervical cancer (or a pre-cancerous condition), she may be eligible for Medicaid Treatment Services under the Breast and Cervical Cancer Prevention and Treatment Act (BCCPTA). Screening data must be provided on the appropriate data forms.

If a woman is screened by a BCCEDP provider who detects an abnormality, but chooses to be evaluated by a non-BCCEDP provider, who eventually detects and diagnoses cancer, she may be eligible for Medicaid Treatment Services under the Breast and Cervical Cancer Prevention and Treatment Act (BCCPTA). Results of all screening and diagnostic services, including final diagnosis, must be provided on the appropriate data forms.

If her Medicaid eligibility is terminated because she no longer requires treatment, she is eligible for reenrollment in the BCCEDP for breast and cervical cancer screening services as long as she meets the BCCEDP eligibility requirements. If she is subsequently diagnosed with breast or cervical cancer (or a pre-cancerous condition), she may be eligible for re-enrollment in Medicaid for the new cancer treatment, even if it is a recurrence of the previous cancer. Appropriate data forms must be completed.

#### WOMEN WHO ARE NOT ELIGIBLE FOR MEDICAID UNDER THE BCCPTA

Women who have already received a cancer diagnosis for breast and/or cervical cancer but were NOT screened or diagnosed by a BCCEDP Provider for that condition, are NOT eligible for Medicaid payment for treatment of that cancer, under the Breast & Cervical Cancer Prevention and Treatment Act covered group.

If a woman indicates that she is not a US citizen, receives SSI, is pregnant, or has a child under the age of 19 living with her, her application will require further evaluation by the DSS. **She may not be eligible for treatment under the BCCPTA covered group**. Many qualified aliens who arrived in the U.S. after August 21, 1996 are barred from receiving Medicaid for 5 years beginning with their date of entry with a qualified alien status. The five-year bar does not apply to certain refugees, asylees, and certain other groups. The determination of her eligibility for Medicaid will lie with the Department of Social Services.

#### **DEFINITION OF A PRE-CANCEROUS CONDITION**

Pre-cancerous conditions of the breast and/or cervix are those which are defined by a physician as needing treatment.

## BREAST AND CERVICAL CANCER PREVENTION AND TREATMENT ACT (BCCPTA): PROCEDURE FOR ENROLLMENT

Once a patient is diagnosed with breast or cervical cancer or a pre-cancerous condition and deemed in need of treatment by a physician, the following procedures must take place:

- The patient will complete and sign a BCCPTA Medicaid Application/Redetermination form. This form will be certified by the case manager or a person that is designated to sign by the respective administrative provider site.
- The case manager will immediately forward the signed copy of the BCCPTA Medicaid Application/Redetermination form to the county or city DSS office where the patient resides. A copy must also be sent to the BCCEDP Central Office.
- The case manager will maintain contact with the patient to ensure that treatment has begun and that any barriers to receiving treatment are addressed. Document all contacts with the patient in the medical record.
- The case manager shall inform the patient in writing that her eligibility for Medicaid through the BCCPTA ends when her treatment has ended. A copy of this letter shall be sent to the treating physician.
- Some patients will have a very short course of treatment (e.g., Leep, conization, etc.) Others will have a prolonged course of treatment (e.g., Tamoxifen for five years). The physician will determine when the course of treatment is completed. The patient shall receive full Medicaid coverage for as long as she is in treatment.
- It is the patient's responsibility to notify Medicaid when her treatment course is completed or if she has a change in her Medicaid eligibility status (e.g. obtains private insurance, etc)
- Once the patient has completed treatment and is no longer eligible for Medicaid, she can be reenrolled in the BCCEDP as long as she meets all of the eligibility criteria for enrollment. It is highly recommended that the case manager contact the patient after her treatment is completed in order assess her eligibility for re-enrollment in the BCCEDP.

#### MEDICAID REDETERMINATION

The Department of Social Services will redetermine Medicaid eligibility on an annual basis. At the time of the annual redetermination, the recipient must provide a statement from her medical provider verifying continued treatment for breast or cervical cancer.

### SAMPLE LETTER TO PHYSICIAN RE: MEDICAID

Today's Date
Re: Patient's Name
Dear Dr
Mshas been enrolled in The Breast and Cervical Cancer Early Detection Program (BCCEDP). This program covers breast and cervical cancer screening and follow-up services until the screening is determined negative/benign or until a diagnosis of breast and/or cervical cancer or a pre-cancerous condition is reached.
Beginning July 1, 2001, The Breast and Cervical Cancer Prevention and Treatment Act (BCCPTA) became effective. Ms is eligible for enrollment in Medicaid because she was enrolled, screened, and/or diagnosed with by a medical provider operating under the BCCEDP. Once enrolled in Medicaid under the BCCPTA, she will be eligible for all Medicaid covered services while under treatment. However, the final determination for eligibility for Medicaid lies with the Department of Social Services.
Once you have determined that Mshas completed her treatment, please provide her with a document indicating this. It will then become her responsibility to present this document to the Department of Social Services. At that time, she will be discharged from Medicaid. If you will kindly notify me (with the patient's consent) that she has completed her treatment, I will be happy to facilitate her re-enrollment into the BCCEDP. Once she is re-enrolled in the program, she will be able to receive future screenings for breast and cervical cancer free of charge. Please remember that re-enrollment in the program does depend on her meeting certain eligibility criteria.
If you have any questions or concerns about Ms
Sincerely,
Case Manager's Name
Address
Phone# Fax#
E-mail address

## **Frequently Asked Questions**

#### **Frequently Asked Questions**

1. A woman has a Pap smear with a result of ASCUS. The plan is to repeat her Pap smear in three months. Is this considered diagnostic work-up?

No. Short-term follow-up Pap tests do not constitute diagnostic work-up and the result of these Pap tests should be recorded on a new Screening Encounter Form. Document on question 21 that no diagnostic work-up is planned.

2. A woman has a hysterectomy for benign reasons, but the physician wants to perform a vaginal Pap test. Will the program pay for this?

No. It is always up to the clinician to determine the plan of care for a woman, but CDC will not reimburse for vaginal Pap tests unless the hysterectomy was performed for cervical neoplasia or the woman had a supracervical hysterectomy, thereby leaving her cervix intact. However, record the results of the vaginal Pap smear on the Screening Encounter Form and, under question 18, record "no" when asked if the Pap smear was paid for by the BCCEDP. This does not affect your reimbursement of the capitated rate.

3. A woman has a mammogram and the radiologist is awaiting films for comparison. Should I record the result as "Assessment Incomplete" on the Screening Encounter Form?

No. Record the result as "Result Pending" or await the final result from the radiologist before recording on the Screening Encounter Form. A result of "Assessment Incomplete" (BIRADS 0) means that the radiologist wants additional imaging studies performed. The results of the additional imaging studies will be recorded on the Breast Diagnostic Encounter Form.

4. A woman comes in for screening and is ineligible for a Pap smear since she has had three consecutive negative MDE documented Pap smears within the last five years. Should a pelvic examination be performed anyway?

A woman should receive a pelvic examination even if she will not receive a Pap smear. Many abnormalities can be found during a pelvic examination that might otherwise go undetected. There is no need to report the findings of the pelvic exam on the Screening Encounter Form; the questions have been removed from the current version of the form. If the patient has only a pelvic exam and not a Pap test, this will not affect your reimbursement rate.

5. A woman has a Pap smear result of Atypical Glandular Cells (AGC) and the clinician plans to repeat the Pap smear in three or four months. Is this appropriate follow-up?

No. The patient must always have diagnostic work-up for a finding of AGC. Simply repeating the Pap smear is insufficient. Follow the Algorithms from the Consensus Guidelines for the Management of Women with Cervical Cytological Abnormalities. There is a high incidence of endometrial cancer with a Pap finding of AGC.

6. The clinician determines that the patient has an abnormal, suspicious for cancer clinical breast examination. The patient is sent for a screening mammogram, which is negative, and the clinician opts not to perform any diagnostic work-up. Is this sufficient work-up?

No. The patient should have been sent for a diagnostic, not a screening, mammogram. Even if the result of the diagnostic mammogram is negative, the patient must then be referred for one or more of the following diagnostic procedures:

- Breast Ultrasound
- Repeat breast examination by a surgeon/breast specialist
- Biopsy/Lumpectomy
- Fine Needle Aspiration

### 7. A woman fails to show up repeatedly for scheduled appointments. How long does the case manager have to follow her?

Once a woman fails to show for three scheduled appointments, the case manager has the option of discharging her from the BCCEDP. However, a certified letter should be sent to the woman explaining the reason for discharging her and giving her the option to re-enroll in the future if she chooses to do so.

8. A woman returns to the clinic for a follow-up Pap smear after a diagnosis of ASCUS four months ago. How is this recorded on the data forms?

For follow-up pap smears (no other tests done), record the visit as "FU" (follow-up) on the Screening Encounter Form. Complete the cervical section and indicate that the CBE and mammogram were "not needed, previously performed" in the CBE and mammogram sections. Do <u>not</u> repeat information already submitted in another screening cycle.

9. Should I report any of the patient's medical history? If so, what form would I use?

We have eliminated the Medical History Survey for FY 2004. Instead, we ask that you obtain information on a new client's last mammogram and Pap test (prior to being enrolled) and report it on the Eligibility Form. This information is relevant to whether or not we are targeting women in need of breast and cervical cancer screening. One of the Performance Indicators is that at least 20% of newly enrolled women must fall in the category of never been screened for cervical cancer or previously having a Pap test more than five years ago.

10. A woman is diagnosed with breast or cervical cancer through the BCCEDP and refuses all forms of treatment with the exception of palliative care for symptom management. Can this woman be referred to Medicaid under the BCCPTA?

Yes. Treatment includes **all forms of treatment prescribed by a physician** for her breast or cervical cancer. This also includes the women for whom pain management with medication is the only form of therapy planned.

11. A woman is enrolled in our program. She is diagnosed with breast cancer. She has a green card with an alien ID number. Will she be accepted into Medicaid under the BCCPTA?

She may not be eligible under the BCCPTA covered group. If she entered the U.S. after August 21, 1996, she will probably be barred from receiving Medicaid for 5 years beginning with her date of entry as a qualified alien. **There are exceptions to this rule**. You should refer the patient to the DSS in the county or city where she resides. A DSS eligibility worker will need to assess the specifics of her case in order to make a determination regarding her eligibility for Medicaid.

## **Billing**

### **BILLING POLICY**

## **Procedure 1: Data Packet and Invoice Received Concurrently:**

- 1.1 Invoice and data packets are stamped as received by the BCC staff.
- 1.2 The Data Manager or designated Data Entry Staff reviews the data packets for accuracy and completeness and highlights any mistakes or missing data fields. Data is entered in BCC database.
- 1.3 <u>If all data forms are complete</u>, the data packet is approved for payment and marked as "OK" beside the patient's name on the itemized invoice. The invoice date is filled in on the invoice date field in the database.
- 1.4 The Data Staff takes the reviewed invoice to the Program Director or Data Manager for a final signature of approval and assignment of budget codes. The original invoice will be stamped ("Approved for Payment") with a final date of approval.
- 1.5 The Data Staff submits the approved original invoice to the Fiscal Office for processing for payment. A copy of the invoice is placed in the file.
- 1.6 The Data Staff sends (via FAX and mail) a copy of the approved invoice and detailed memo to the Provider Site.
- 1.7 <u>If all data forms are NOT complete</u>, the data packet is <u>not</u> approved for payment and marked as "NA" (Not Acceptable) beside the patient's name on the itemized invoice. The invoice date field in the database is left blank.
- 1.8 Missing or incorrect data fields are highlighted on the original data form. A copy of the data form(s) with incomplete information is returned to the Provider for correction and resubmission.
- 1.9 The Data Staff will amend the submitted invoice indicating the actual number of complete packets that are approved for payment.
- 1.10 A copy of the original amended invoice will be returned to the Provider with the incomplete data forms. An accompanying memo from the Data Manager will provide further detail on the type of information missing.
- 1.11 The Provider site will be instructed to resubmit the completed data packets/forms in the next month's data submission with the patient listed on a new invoice.
- 1.12 The Data Staff takes the invoice post-review to the Program Director or Data Manager for final approval and budgetary coding. The original invoice is stamped ("Approved for Payment") with a final date of approval.
- 1.13 The Data Staff submits the signed invoice to the Fiscal Office for processing for payment.
- 1.14 The Data Staff sends (via FAX and mail) a copy of the approved invoice and detailed memo to the Provider Site.

## **Procedure 2: Invoice Only Received**

- 2.1 If an invoice is received, but no data had been received, no further action will be taken on the invoice by the Data Staff or Business Unit. **To ensure prompt payment, data must accompany all invoices.**
- 2.2 The Data Staff, who reviews the invoice, will appropriately check the explanatory item on the form called the *Billing Problem Memo* (second check box on Memo) and FAX it to the Provider Site immediately.
- 2.3 The Data Staff copies the invoice and marks "NA" beside each patient's name on the itemized invoice. The Data Staff mails the invoice back to the Provider for resubmission

Revised 06/17/2003 71

- with the complete data packets. The Memo is also sent to the Provider and a copy of both invoice and Memo are kept in the BCC files.
- 2.4 See Procedure 1 and follow upon resubmission of invoice and data packets.

### **Procedure 3: Data Packets Only Received**

- 3.1 If data packets are received, <u>but</u> there is no invoice, the data packets will be date stamped as received by the state office.
- 3.2 The Data Manager or designated Data Entry Staff reviews the data packets for accuracy and completeness and highlight any mistakes or missing data fields.
- 3.3 The Data Staff will enter the data into the BCC database, leaving the invoice date field blank in the database until an invoice is received and approved.
- 3.4 The Data Staff will appropriately check the explanatory item on the form called the *Billing Problem Memo* (third check box on the Memo) and FAX it to the Provider Site immediately. Patients' names and dates of service will be listed on the Memo under the detail section.
- 3.5 Packets with missing data or errors will be returned to the Provider along with the Memo.
- 3.6 See Procedure 1.1 and follow upon resubmission of invoice and data packets.

Revised 06/17/2003 72

### **GETTING PAID**

- 1. Complete all information on the required Forms: Eligibility Form, Screening Encounter Form (Diagnostic Encounter Forms may be completed at a later date).
- 2. Provide the information required on the sample invoice, making sure that Provider letterhead is used. The following information is required on second page attached to the invoice: patient's name, SSN, screening date of service. Reserve a column for BCCEDP use—BCCEDP staff will review each data packet and indicate which packets are approved for payment.
- 3. Mail the invoice and the data packets in a manila envelope to:

Virginia Department of Health Virginia Breast and Cervical Cancer Early Detection Program PO Box 2448, Room 135 Richmond, Virginia 23219

- 4. Names on the invoice will be checked against the names on the forms in the data packet. Each form will then be checked for completed data.
- 5. Any data packets with incomplete or missing data will be returned to the Provider Site Case Manager/Coordinator for correction/completion. The invoice will be amended to show the clients approved for payment.
- 6. The approved invoice will be signed by the Program Director and forwarded to the Virginia Department of Health fiscal office for payment.
- 7. Payment typically takes between 30 to 60 days to be sent to the Provider.
- 8. Incomplete data packets returned to the case manager may be re-submitted for payment in the next month's billing cycle when they are corrected or completed. The name of the client should be included in the new invoice.

Revised 06/17/2003 73

## **Provider Letterhead**

## **SAMPLE INVOICE**

Invoi	ice Date:	Federal Tax ID#		
Invoic	ee #	Contract #		
Submi	itted by:			
TO: Virginia Department of Health Virginia Breast and Cervical Cancer Early Detection Program 109 Governor Street, Eighth Floor (P.O. Box 2448) Richmond, Virginia 23219				
Reimbursement is requested for expenses incurred on project entitled <i>BCCEDP Screening</i> (see attached Patient List).				
Reimb	oursement of expenses incurred to screen	_ women @ \$320 each = \$		
Approved by VDH for payment: women @ \$320 each = \$				
Please remit \$ to:				
Provid	ler Site Name			

Address Address

\*Social Security Number is requested but not required; if not used, please create an identifying number for the client(s).

PLEASE NOTE: Payment will be approved only for clients with required data forms completed.

# **Provider Letterhead**

Invoice Date:	Invoice #

Data submitted on the following BCCEDP Patients:

	T	T		
		Screening		VDH USE ONLY
		Date of	Social Security	All Data Forms
#	Patient Name	Service	Number*	Included?
π	T attent tvanic	Scrvice	Number	meradea:

## **BCCEDP APPROVED MEDICARE PROCEDURE CODES**

## (Based on the Year 2003 Medicare Rate Schedule) Effective 3/01/03 to 7/29/04

BREAST	CPT	FEE
	CODE	
Screening		
Screening Mammogram, bilateral (two view film study of each breast)	76092	72.76
	76092 TC	40.30
	76092 26	32.46
Diagnostics		
Diagnostic/Follow-UpUnilateral Mammogram	76090	66.74
	76090 TC	34.61
	76090 26	32.13
Diagnostic/Follow-UpBilateral Mammogram	76091	83.09
	76091 TC	43.22
	76091 26	39.87
Stereotactic localization guidance for breast biopsy or needle	76095	309.91
placement (eg, for wire localization or for injection), each lesion,	76095 TC	236.71
radiological supervision, and interpretation	76095 26	73.20
Mammographic guidance for needle placement, breast (e.g., for wire	76096	68.96
localization or for injection), each lesion, radiological supervision and	76096 TC	43.22
interpretation	76096 26	25.75
Radiological examination, surgical specimen	76098	21.54
	76098 TC	13.97
	76098 26	7.57
Ultrasound, breast (s) (unilateral or bilateral), B-scan and/or real time	76645	59.35
with image documentation	76645 TC	34.61
	76645 26	24.74
Ultrasonic guidance for needle placement (e.g., biopsy, aspiration,	76942	128.06
injection, localization device), imaging supervision and interpretation	76942 TC	97.10
	76942 26	30.96
Puncture aspiration of cyst of breast (surgical procedure only)	19000	68.74
Puncture aspiration of cyst of breast, each additional cyst	19001	41.42
Breast biopsy; percutaneous, needle core, not using imaging guidance 19100		91.36
(surgical procedure only)		
Breast biopsy; open, incisional	19101	274.59

physician Papillomavirus, human, amplified probe technique	87621	45.95
Pap smear, reported in Bethesda System requiring interpretation by	88141	46.59
physician supervision		
Pap smear, reported in Bethesda System, manual screening under	88164	14.76
Screening		
CERVICAL		
The Control of San Street	88307 26	78.20
examination requiring microscopic evaluation of surgical margins	88307 TC	66.08
Breast, excision of lesion-surgical pathology, gross and microscopic	88307	144.28
1, 9, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1,	88305 26	36.91
not requiring microscopic evaluation of surgical margins	88305 TC	46.92
Breast biopsy-surgical pathology, gross and microscopic examination,	88305	83.83
	88173 26	68.30
report	88173 TC	39.61
Cytopathology, evaluation of fine needle aspirate; interpretation and	88173	107.90
by termination of the determination and quality of specimen(s)	88172 26	29.53
cytohistologic study to determine adequacy of specimen(s)	88172 TC	13.97
Cytopathology, evaluation of fine needle aspirate; immediate	88172	43.50
	10022 16	
The market with the same and s	10022 TC	123.13
Fine needle aspiration with imaging guidance	10021 20	130.40
	10021 10	
I me needle aspiration without maging gardanee	10021 10021 TC	121.57
Fine needle aspiration without imaging guidance	10021	121.34
additional lesion	1/2/1	70.00
Preoperative placement of needle localization wire, breast; each	19291	76.80
Preoperative placement of needle localization wire, breast	19290	138.04
by a preoperative radiological marker		
radiological marker, open; each additional lesion separately identified	1/120	130.02
Excision of breast lesion identified by preoperative placement of	19126	138.02
radiological marker, open; single lesion	1/143	300.00
Excision of breast lesion identified by preoperative placement of	19125	380.68
aberrant breast tissue, duct lesion, nipple or areolar lesion, open, one or more lesions		
Excision of cyst, fibroadenoma, or other benign or malignant tumor,	19120	338.38
biopsy device using imaging guidance  Excision of exet, fibroadenesse, or other benign or malignant tumor	19120	358.58
Breast biopsy; percutaneous, automated vacuum assisted or rotating	19103	528.14
Biopsy of breast; percutaneous, needle core using imaging guidance	19102	228.02
Rioney of broast parautaneous needle core using imaging guidence	10102	228.02

Diagnostic		
Colposcopy without biopsy (surgical procedure only)	57452	107.95
Colposcopy with biopsy and endocervical curettage (surgical	57454	148.08
procedure only)		
Colposcopy with biopsy (s) of the cervix	57455	132.93
Colposcopy with endocervical curettage	57456	125.57
Cervical biopsy, interpretation-surgical pathology, gross and	88305	83.83
microscopic examination	88305 TC	46.92
	88305 26	36.91
OFFICE VISITS		
New Patient-Office Visit (10 minutes face to face)	99201	31.24
New Patient-Office Visit (20 minutes face to face)	99202	55.80
New Patient-Office Visit (30 minutes face to face)	99203	82.69
New Patient-Office Visit (45 minutes face to face)	99204	118.15
New Patient-Office Visit (60 minutes face to face)	99205	151.04
Established Patient-Office Visit (5 minutes face to face)	99211	18.29
Established Patient-Office Visit (10 minutes face to face)	99212	32.54
Established Patient-Office Visit (15 minutes face to face)	99213	45.71
Established Patient-Office Visit (25 minutes face to face)	99214	71.55
Established Patient-Office Visit (40 minutes face to face)	99215	104.94
Consultation Visit-15 minutes face to face with patient	99241	42.27
Consultation Visit-30 minutes face to face with patient	99242	78.56
Consultation Visit-40 minutes face to face with patient	99243	104.08

Modifier Codes T and 26: Certain procedures are a combination of a physician component and a technical component. When the physician component is reported separately, the service may be identified by adding the modifier "26" to the usual procedure number. When the technical component is reported separately, the service may be identified by adding the modifier "T" to the usual procedure number.

All codes new to the list are **bolded.** 

# LISTED BELOW ARE EXAMPLES OF PROCEDURES THAT ARE NOT REIMBURSABLE THROUGH THE BCCEDP

PROCEDURE	CPT CODE	FEE
Loop electrode biopsy(s) of the cervix	57460	263.73
Loop electrode excision	57522	239.01
Conization of the Cervix	57520	278.61
Endometrial Biopsy	58100	100.34
Pelvic Ultrasound	76856	82.17
Any treatment of breast cancer, cervical	Varies	Varies
intraepithelial neoplasia and cervical cancer		

# **Sample Letters**

August 12, 2002

Jane Doe 161 Harm's Way Little Town, Va. 24153

Dear Ms. Doe,

Recently, you informed me that you have obtained Medicare coverage. According to the "Every Woman's Life" program guidelines, you are no longer eligible to participate in the program; however, we can provide a list of local doctors and mammography facilities in your area upon request. You may also contact Carilion Physician Referral at 1-800-422-8482 and they will assist you with finding a physician.

I am pleased that you have taken a positive step in assuming responsibility for your health by having a mammogram and Pap smear, and I appreciate the opportunity to assist you in obtaining these services. Since Medicare provides coverage for these services, I hope you will continue to have a mammogram and Pap smear every year. Some women feel that getting exams done once means that they don't have to get them again. On the contrary, these exams are most useful when scheduled at regular intervals so that early changes can be detected and treated.

Please take time to take care of yourself. Do it for yourself and those who depend on you! If you have questions or concerns, do not hesitate to call me toll free at 1-877-388=4620.

With warmest regards,

Health Screening Coordinator Every Woman's Life August 8, 2002

Ms. Jane Doe 161 Harm's Way Little Town, Va. 24153

Dear Ms. Doe,

You have been scheduled for a surgical consultation as follows:

Physician: Dr. Dudley Doolittle

Date: Tuesday, August 20, 2002

Time 2:30 p.m.

Telephone: (549) 888-8888

Location: Little Town Surgical Associates

The clinic will forward a copy of your records to the surgeon's office for review. You will need to pick up your mammogram and/or ultrasound films along with a copy of the reports and take them with you to the appointment. For directions, please call the surgeon's office at the above number.

If you cannot keep this appointment, please call me as soon as possible or call the surgeon's office to reschedule. In the meantime, please feel free to call me if you have any questions or concerns at 540-777-7777 or toll free at 1-877-888-8888.

Sincerely,

July 19, 2002

Ms. Jane Doe 161 Harm's Way Little Town, Virginia 24153

Dear Ms. Doe,

We are pleased that you have taken a positive step in assuming responsibility for your health. This service was funded by *Every Woman's Life*, and sponsored by Carilion Health System. We encourage you to practice the recommendations taught to you at the Clinic and to continue to have regular annual checkups. The screening results from your recent visit to the clinic and the Carilion Breast Care Center are as follows:

Mammo	gram (x-ray of the breast(s))
	_No evidence of breast cancer
	_Other:
Pap Sme	ear (sample of cells from the cervix (mouth of womb), or vagina if you have had a tomy):
	_No evidence of cancer
	_Other

Your mammogram should be done again in **one year** and your Pap smear in **one year**. Please call the "Every Woman's Life" Program for an appointment one month ahead of time at 1-888-888 (toll free)

If you have any questions, do not hesitate to call our office. Congratulations on taking this important step in protecting your health.

Sincerely,

February 23, 2002

Ms. Jane Doe 161 Harm's Way Little Town, Va. 24153

Dear Ms. Doe,

It's that time of year! You are due for your annual Pap test and mammogram in April.

The EveryWoman's Life Program continues to provide free mammograms and Pap tests to eligible women in the state of Virginia. It is necessary to re-enroll in the program each year to receive these services. If you are interested in re-enrolling, please contact me at **1-888-888-8888 (toll free)**.

Many women schedule these exams regularly as part of their plan to take care of themselves. Some women feel that getting these exams done once means that they don't have to get them again. On the contrary, these exams are most useful when done at regular intervals so that early changes can be detected and treated.

We hope that you will take time to take care of yourself. Do it for yourself and do it for those who depend on you.

We will be happy to schedule your visit when you call.

With warmest regards,

# **Appendices**

### APPENDIX A: ALGORITHMS FROM THE CONSENSUS GUIDELINES FOR THE MANAGEMENT OF WOMEN WITH CERVICAL CYTOLOGICAL ABNORMALITIES

—to download a copy, refer to the ASCCP website:

http://www.asccp.org/consensus/cytological.shtml

### Definitions of Terms Utilized in the Consensus Guidelines

**Colposcopy** is the examination of the cervix, vagina, and, in some instances the vulva, with the colposcope after the application of a 3-5% acetic acid solution coupled with obtaining colposcopically-directed biopsies of all lesions suspected of representing neoplasia.

**Endocervical sampling** includes obtaining a specimen for either histological evaluation using an endocervical curette or a cytobrush or for cytological evaluation using a cytobrush.


**Endocervical assessment** is the process of evaluating the endocervical canal for the presence of neoplasia using either a colposcope or endocervical sampling.

**Diagnostic excisional procedure** is the process of obtaining a specimen from the transformation zone and endocervical canal for histological evaluation and includes laser conization, cold-knife conization, loop electrosurgical excision (i.e., LEEP), and loop electrosurgical conization.


**Satisfactory colposcopy** indicates that the entire squamocolumnar junction and the margin of any visible lesion can be visualized with the colposcope. **Endometrial sampling** includes obtaining a specimen for histological evaluation using an endometrial biopsy or a "dilatation and curettage" or hysteroscopy.




# Management of Women with Atypical Squamous Cells of Undetermined Significance (ASC-US)




# Management of Women with Atypical Squamous Cells of Undetermined Significance (ASC-US) In Special Circumstances




## Management of Women with Atypical Squamous Cells: Cannot Exclude High-grade SIL (ASC - H)




### Management of Women with Atypical Glandular Cells (AGC)




### Management of Women with Low-grade Squamous Intraepithelial Lesions (LSIL) \*




# Management of Women with Low-grade Squamous Intraepithelial Lesions In Special Circumstances



# Management of Women with Low-grade Squamous Intraepithelial Lesions In Special Circumstances



### Management of Women with High-grade Squamous Intraepithelial Lesions (HSIL) \*



# APPENDIX B: BCCPTA MEDICAID APPLICATION/REDETERMINATION FORM

COMMONWEALTH OF VIRGINIA
DEPARTMENT OF SOCIAL SERVICES

# Breast and Cervical Cancer Prevention and Treatment Act (BCCPTA) Medicaid Application/Redetermination

AG DATE RECEIVED:	ENCY USE ONLY
CASE NAME/NUMBER:	
LOCALITY:	WORKER

				LOCALITY:	WORKER
Please comple	te all sections.	If you need assistance, please contac	t an eligibility worker	at your local Departme	nt of Social Services.
1. IDENTIFYIN	NG INFORMAT	ION			
LAST NAME:		FIRST NAME:		MI:	SOCIAL SECURITY NUMBER:
ADDRESS:	Hi	CITY:	ST ST	ATE: ZIP:	STATE OF RESIDENCE:
MAILING ADDRESS	S (If ferent):	T VITY-	ST	ATE: ZIP:	HOME PHONE #: DAYTIME PHONE #:
2. ADDITION	AL INFORMAT	ON			
	☐ WHITE ☐ BLACK ☐ HISPANIC	☐ AMERICAN INDIAN/ALASKA NATIVE ☐ ASIAN/PACIFIC ISLANDER ☐ OTHER	MARITAL STATU	S: NEVER MARI  MARRIED  SEPARATED	WIDOWED
DATE OF BIRTH: _		PLACE O	OF BIRTH:		
U. S. CITIZEN?	YES □ NO □	] IF NO, ALIEN NUMBER:			
DO YOU RECEIVE SSI? YES NO ARE YOU PREGNANT? YES NO DO YOU HAVE A CHILD(REN) UNDER AGE 19 LIVING WITH YOU? YES NO					
DO YOU HAVE HE	ALTH INSURANCE	?? YES NO IF YES, C	COMPANY NAME:		
POLICY #:		EFFECTIVE DATE:	TYPE C	OF COVERAGE:	
DID YOU RECEIVE MEDICAL CARE IN ANY OF THE THREE MONTHS BEFORE THIS APPLICATION? YES NO IF YES, LIST MONTHS:					
3. BCCPTA CERTIFICATION					
I CERTIFY THAT THE ABOVE NAMED INDIVIDUAL IS A VIRGINIA BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAM (BCCEDP) PARTICIPANT (TITLE XV) AND IS ELIGIBLE FOR MEDICAID UNDER THE BREAST AND CERVICAL CANCER PREVENTION AND TREATMENT ACT OF 2000.					
SCREENING DATE	≣:	DIAGNOSIS DATE:	FACILITY/SERVICE SITE:		PHONE #:
SIGNATURE OF B	BCCEDP CASE MA	SIGNATURE OF BCCEDP CASE MANAGER:			

#### YOUR RIGHTS AND RESPONSIBILITIES

## By signing below, I agree to the following: I have the right to:

- Be treated fairly and equally regardless of my race, color, religion, national origin, gender, political beliefs or disability consistent with state and federal law and to file a complaint if I feel I have been discriminated against.
- Have my eligibility for Medicaid benefits determined within 10 working days of receipt of my application at my local department of social services.
- Appeal and have a fair hearing if I am: (1) not notified in writing of the decision regarding my application; (2) denied benefits from the Medicaid program; or (3) dissatisfied with any other decision that affects my receipt of Medicaid benefits.

#### I have the responsibility to:

- Not purposely withhold information, or give false information and understand if I do so my Medicaid coverage may be denied or ended.
- Report any changes in information provided on this form within 10 days to my local department of social services.
- Cooperate with a review of my Medicaid eligibility by Quality Control and understand that refusing to cooperate will make me ineligible for Medicaid until I cooperate with a review.

### I further understand and agree that:

- This application is used only to apply for Medicaid under the Breast and Cervical Cancer Prevention and Treatment Act coverage group and that in order to apply under other coverage groups I must complete another application.
- The Department of Medical Assistance Services and the Department of Social Services are authorized to obtain any verification necessary to establish my eligibility for Medicaid.
- The Department of Medical Assistance Services has the right to eceive payme ts for services are supplies from insurance companies and other liable sources as reimbursement for medical services received by me.
- ♦ Each provider of medical services may release any medical records pertaining to any services received by re.
- I am assigning my rights to medical support and other third party payment to t e L partment of Medical As istar se ervir es in der to receive benefits from the Medicaid program.

I declare that all information I have given on this application is true and correct to the best of my knowledge and belief. I understand that if I give false information, withhold information or fail to report a change promptly or on purpose I may be breaking the law and could be prosecuted for perjury, larceny and/or fraud. I understand that my signature on this application signifies, under penalty of perjury, that I am a U.S. citizen or alien in lawful immigration status.

this application signifies, under penalty of perjury, that ram a 0.5. chizer	of alleft in lawful infinigration status.
Signature or Mark	Date
Witness/Authorized Representative	Date
Check one of the following:	VOTER REGISTRATION
vote will remain confidential. A decision to apply to register to vote and for voter registration purposes. If you believe that someone has interfe	sistance or services that you will be provided by this agency. A decision not to apply to register to d the office where your application was submitted will also remain confidential and may only be used eared with your right to register or to decline to register to vote, your right to privacy in deciding whether file a complaint with: Secretary of Virginia State Board of Elections, Ninth Street Office Building, 200

## APPENDIX C: MEDICAID BCCPTA POLICY (M0320.312)

### Virginia DSS, Volume XIII

M0320.312

# M0320.312 BREAST AND CERVICAL CANCER PREVENTION AND TREATMENT ACT (BCCPTA)

#### A. Policy

The Breast and Cervical Cancer Prevention and Treatment Act (BCCPTA) of 2000 (P.L. 106-354) provides for payment of medical services for certain women with breast and cervical cancer. Virginia has chosen to cover this group beginning July 1, 2001.

Women eligible in this group have been screened by a medical provider operating under the Center for Disease Control and Prevention's (CDC) Breast and Cervical Cancer Early Detection Program and have been certified as needing treatment for breast or cervical cancer, including pre-cancerous conditions. These women must be under age 65 and must not have creditable health insurance coverage for treatment of breast or cervical cancer.

# B. Nonfinancial Eligibility

# 1. Required Nonfinancial Requirements

BCCPTA women must meet the following Medicaid nonfinancial requirements in chapter M02:

- citizenship/alien status;
- *Virginia residency*;
  - social security number provision/application requirements;
  - assignment of rights to medical benefits requirements;
  - application for other benefits; and
  - institutional status.

In addition, BCCPTA women must not be eligible for Medicaid under the following mandatory categorically needy covered groups:

- LIFC:
- MI Pregnant Women;
- SSI recipients.

### 2. Creditable Health Insurance Coverage

BCCPTA women must not have creditable health insurance coverage for the treatment of breast or cervical cancer. Creditable health insurance coverage includes:

- a group health plan;
- health insurance coverage under any hospital or medical service policy or certificate, hospital or medical service plan contract or health maintenanc organization contract offered by a health insurance issuer;
- Medicare;
- Medicaid;
- armed forces insurance;
- a medical care program of the Indian Health Service (IHS) or of a tribal organization;
- a state health risk pool.

### Virginia DSS, Volume XIII

M0320 312

There may be situations where a woman has creditable health insurance coverage a defined above, but the coverage does not include treatment of breast or cervical cancer due to a period of exclusion or exhaustion of lifetime benefits.

C. Financial Eligibility

There are no Medicaid financial requirements for the BCCPTA covered group. The CDC Breast and Cervical Cancer Early Detection Program has income and resource requirements that are used to screen women for this program.

#### D. Application Procedur

The application procedures for women who meet the BCCPTA non-financial requirements have been streamlined to facilitate the prompt enrollment and immediate access to services for women who are in need of treatment for breast or cervical cancer. In addition to the nonfinancial information required to evaluate eligibility in the BCCPTA covered group, the following information is needed for enrollment in Medicaid:

- name,
- address.
- sex and race.
- date of birth,
- country of origin and entry date, if an alien.

Women who meet the description of individuals in the LIFC, MI pregnant women of SSI recipients covered groups must complete the appropriate Medicaid application for the covered group and must have a Medicaid eligibility determination complete prior to determining their eligibility in the BCCPTA covered group. If not eligible in the LIFC, MI pregnant women or SSI recipients covered groups, then determine their eligibility in the BCCPTA covered group.

### 1. Application Form

The BCCPTA Medicaid Application/*Redetermination*, form #032-03-384, was developed for this covered group only. The application includes the *Breast and Cervical Cancer Early Detection Program* certification of the woman's need for treatment and the information needed to determine the nonfinancial eligibility in the BCCPTA covered group. Appendix 1 to this subchapter contains a copy of the BCCPTA Medicaid Application/*Redetermination*.

If eligibility in another Medicaid covered group must first be determined, the applicant must be given the appropriate Medicaid application.

### 2. Application Processing Time Frames

BCCPTA Medicaid applications filed by women who do not meet the description of an individual in the LIFC, MI pregnant women or the SSI recipients covered groups must be processed within 10 working days of the agency's receipt of the signed application.

BCCPTA Medicaid applications filed by women who meet the description of an individual in the LIFC, MI pregnant women or the SSI recipients covered groups must be processed as soon as possible, but no later than 45 days of the agency's receipt of the signed application.

### Virginia DSS, Volume XIII

M0320 312

#### 3. Notices

If the BCCPTA Medicaid application is the only application required and no additional information is required, the eligibility decision must be made immediately and applicant must be notified of the decision within 10 working days of the agency's receipt of the application.

If a decision cannot be made within 10 working days of receipt of the BCCPTA application, the worker must send a "Notice of Action on Medicaid", form #032-03-008, on the 10<sup>th</sup> day stating why action has not been taken, specifying what information is needed and a deadline for submitting the information.

#### E. Entitlement

# 1. Entitlement Begin Date

Medicaid eligibility in the BCCPTA covered group can begin no earlier than July 1, 2001. Eligibility under this covered group is met the beginning of the month the screening is completed if the woman later has a positive diagnosis as a result of the screening and is determined to be in need of treatment for her breast and/or cervical cancer.

Eligible BCCPTA women are entitled to full Medicaid coverage beginning the first day of the individual's application month if all eligibility requirements are met in that month, but no earlier than July 1, 2001.

## 2. Retroactive Entitlement

Retroactive coverage is applicable to this covered group if the individual was screened by a medical provider operating under the CDC *Breast and Cervical Cancer Early Detection Program* and diagnosed as needing treatment for breast or cervical cancer in the retroactive month(s). However, coverage can begin no earlier than July 1, 2001.


### F. Enrollment

The PD for BCCPTA women is "66".

#### G. Redetermination

Annual redetermination requirements are applicable to the BCCPTA covered group. Section 3 on the BCCPTA Application/Redetermination, form is not applicable at redetermination. At the time of the annual redetermination, the recipient must provide a statement from her medical provider verifying continued treatment for breast or cervical cancer.

Δ	PPENDIX D.	PURLIC	EDUCA	TION 8	& OUTREAC	CH WORK PLAN
		I UDLIC			a collina	





## Appendix #1 - Public Education & Outreach Plan

Instructions: Please describe in the table below how you will achieve the following objectives during FY 2004. Complete each column of the table with the exception of the Progress Report column. This column will be completed by the Administrative Provider Site with the submission of the Administrative Provider Site Annual Report.

## GOAL: Screen 100% of Screening Allocation

Objectives	Strategies	Timeline	Person(s) Responsible	Progress Report
1. Identify and screen				(To be completed with the
eligible women who have				submission of the
never or rarely been				Administrative Provider Site
screened for cervical cancer.				Annual Report)
2. Identify and screen				
minority women who are				
eligible for BCCEDP				
services.				

3. Identify and screen			
physically and/or mentally			
disabled women who are			
eligible for BCCEDP			
services.			
Sel vices.			
4. Identify and re-screen	-		
women who have previously			
been enrolled and screened			
in the BCCEDP.			
5. Facilitate local coalition	-		
building activities in order			
to increase the number of			
eligible women who are			
screened through the			
BCCEDP.			
		I .	

6. Increase the capacity to screen women by collaborating with present and/or potential screening partners.		